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ABSTRACT 
 
Exchange of macromolecules between the nucleo- and cytoplasm is provided by the nuclear transport 
system (NTS). Karyopherins represent essential components of NTS) by serving as nuclear transport 
receptors/adaptor proteins. Dysregulation of karyopherins in (hepato-) carcinogenesis, including the 
pivotal nuclear import factor karyopherin-α2 (KPNA2), has been previously reported. However, the 
functional and regulatory role of KPNA2 in hepatocellular carcinoma (HCC) remains incompletely 
understood. To further characterize KPNA2 in this context, mass spectrometry-based proteomics was 
combined with functional/mechanistic cell-based approaches and data derived from murine and human 
HCC samples. Quantitative mass spectrometry upon siRNA-mediated KPNA2 knockdown in HCC cells 
revealed the microtubule-related oncoprotein stathmin among the most downregulated proteins. KPNA2 
depletion resulted in impaired colony formation and tumor cell migration in HCC cells, which could be 
recapitulated by direct knockdown of stathmin. Having identified stathmin as functional relevant 
“downstream” target of KPNA2 the underlying molecular mechanism of KPNA2-dependent stathmin 
regulation was dissected. Out of several candidates the transcription factors E2F1 and TFDP1 were 
identified as transport substrates of KPNA2 and to be retained in the cytoplasm upon KPNA2 ablation 
followed by reduced STMN1 expression. Finally, significant correlations of STMN1 with E2F1/TFDP1 and 
KPNA2 expression were found based on data derived from murine HCC models and human HCC cohorts 
with high KPNA2 and STMN1 expression being associated with poorer patient outcome.  
Taken together, these data suggest that KPNA2 regulates STMN1 by mediating nuclear import of 
E2F1/TFDP1 and thereby provide a functionally relevant link between the NTS and microtubule-interacting 
proteins in HCC. Though further studies are required, interfering with nuclear import factors such as 
KPNA2 could represent a promising therapeutic approach in liver cancer.   
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KURZDARSTELLUNG 
 
Das Kerntransportsystem (nuclear transport system, NTS) gewährleistet den Austausch von 
Makromolekülen zwischen dem Nukleo- und Zytoplasma. Karyopherine stellen essentielle Komponenten 
des NTS dar, indem sie als nukleäre Transportrezeptoren bzw. Adapterproteine fungieren. Eine 
Dysregulation von Karyopherinen, einschließlich des wichtigen nukleären Importfaktors Karyopherin-α2 
(KPNA2), in der (Hepato-) Karzinogenese, wurde bereits beschrieben. Allerdings sind die damit 
verbundenen funktionellen Effekte und deren Mechanismen bislang nur unzureichend aufgeklärt. Um in 
diesem Kontext KPNA2 näher zu charakterisieren, wurde Massenspektrometrie-basierte Analytik mit 
funktionellen/mechanistischen zell-basierten Ansätzen und Daten aus murinen und humanen HCC 
(hepatozelluläres Karzinom)-Proben kombiniert. Mit Hilfe der quantitativen Massenspektrometrie konnte 
nach siRNA-vermitteltem Knockdown von KPNA2 in HCC Zellen das Mikrotubuli (MT)-interagierende 
Onkoprotein Stathmin (STMN1) als eines der am stärksten herunterregulierten Proteine identifiziert 
werden. Der KPNA2-Knockdown führte ferner zu einer verringerte Klonogenität und einem verringerten 
Migrationsvermögen der HCC Zellen, welche auch nach direktem Knockdown von Stathmin beobachtet 
werden konnten. Da sich Stathmin somit als funktionell relevantes “downstream target” von KPNA2 
darstellte, wurde der zu Grunde liegende Mechanismus genauer untersucht. Aus einer Gruppe von 
mehreren Kandidaten konnten die Transkriptionsfaktoren E2F1 und TFDP1 als Cargos von KPNA2 
identifiziert werden, die nach KPNA2 Knockdown einen Importdefekt mit konsekutiver Verringerung der 
STMN1 Expression aufwiesen. Darüber hinaus fanden sich signifikante Korrelationen zwischen der STMN1 
und der E2F1/TFDP1 sowie der KPNA2 Expression in den murinen HCC Proben und in HCC 
Patientenkollektiven, wobei eine hohe KPNA2- und STMN1-Expression mit einer schlechten Prognose 
verbunden war.  
Zusammenfassend weisen die genannten Daten darauf hin, dass KPNA2 über den nukleären Import von 
E2F1/TFDP1 die STMN1-Expression reguliert und stellen damit eine funktionell relevante Verbindung 
zwischen dem NTS und MT-interagierenden Proteinen im HCC her. Vorbehaltlich noch weiterer 
erforderlicher Untersuchungen, könnten nukleäre Importfaktoren wie KPNA2 vielversprechende 
therapeutische Zielstrukturen im HCC darstellen.  
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1 INTRODUCTION 
1.1 Hepatocellular carcinoma 
1.1.1 Etiology and prevalence of HCC 
Liver cancer comprises several histologically different primary malignancies including hepatocellular 
carcinoma, cholangiocarcinoma (intrahepatic bile duct carcinoma) and hepatoblastoma [1, 2]. 
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with increasing incidence 
worldwide. With almost 800,000 new cases a year, HCC is the fifth most frequent cancer in men and the 
ninth most frequent cancer in women. Therapeutic options are limited making HCC the second most lethal 
malignancy after lung cancer [3–5].  
HCC usually develops out of chronic liver disease. Around 85% of HCC cases arise from chronic hepatitis B 
or C viral infection (HBV/HCV), which increase the lifetime risk of developing HCC by 15-20 fold compared 
to the non-infected population [4, 6]. Both infections endorse the development of liver cirrhosis, which 
further promotes hepatocarcinogenesis [4]. Furthermore, alcoholic fatty liver disease (AFLD) and non-
alcoholic fatty liver disease (NAFLD), which can progress to alcoholic steatohepatitis (ASH) and non-
alcoholic steatohepatitis (NASH) [7–9], aflatoxin-B1-contaminated food and with lower frequency 
metabolic disorders like hereditary haemochromatosis can contribute to the development of HCC [8, 9]. 
Due to the high incidence rate of HBV and HCV infections along with the widespread contamination of 
agricultural products with aflatoxin-B1, HCC is especially prevalent in less developed regions such as the 
sub-Saharan Africa, and Eastern and South-Eastern Asia [3, 4, 10]. While HBV is usually vertically 
transmitted from mother to child in these high-risk areas, HBV in the western world and HCV in general 
are predominantly horizontally transmitted (e.g. by sexual intercourse, drug abuse) [4, 8]. HBV infections 
and therefore future HCC cases are decreasing in Asian countries due to the successful establishment of 
vaccination programs [11]. In contrast, the great number of HCV infections in the 1960s and 1970s and the 
raising number of lifestyle-related incidences of obesity-related metabolic disease are leading to a 
dramatic increase in  HCC cases in former low-incidence areas such as the United States and Canada [6, 9, 
12]. 
1.1.2 Pathogenesis of HCC 
In HCC, the malignant transformation progresses through a multi-step process as summarized in 
Figure 1.1. Liver diseases of different etiologies cause hepatocyte damage and therefore induce infinite 
cycles of cell injury and regeneration, eventually leading to chronic liver disease and ultimately to liver 
cirrhosis. Cirrhosis is marked by a growth arrest (senescence) of hepatocytes, abnormal liver nodules and 
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liver scarring. In the further process, hyperplastic nodules progress to dysplastic nodules and finally to HCC 
and thereby increasingly harbor abnormal cytological features (e.g. nuclear crowding) and genomic 
instability [2]. Altogether, this malignant transformation process can take 30 years or more [13, 14]. 
 
Figure 1.1: Schematic depiction of the multi-step process of hepatocarcinogenesis. Liver diseases of different 
etiologies cause necrosis, which further fosters hepatocyte proliferation. This process gives rise to chronic liver 
disease and eventually to liver cirrhosis. Abnormal liver nodules develop and progress to hyperplasic and 
dysplastic nodules and finally to HCC. Reprinted with permission from [2]. 
 
Complementary to the multi-step model of liver carcinogenesis, the stem cell model suggests that HCC 
cells originate from progenitor cells or de-differentiated transformed cells, paralleling the behavior of 
embryonic stem cells and cancer stem cells [15]. 
1.1.3 Molecular alteration in HCC 
The hallmarks of cancer, first postulated by Hanahan and Weinberg in 2000, summarize six complementary 
mechanisms that drive carcinogenesis and tumor progression. Originally, these hallmarks comprised the 
abilities of tumor cells to sustain unlimited proliferation, evade the action of tumor suppressors, resist 
apoptosis, induce angiogenesis, harbor replicative immortality and are capable of invasion and metastasis 
[16]. Revising these hallmarks, Hanahan and Weinberg later complemented the described mechanisms by 
the so-called emerging hallmarks [17]. Therefore, the next generation of the hallmark of cancer includes 
reprogramming of the cellular energy metabolism and evasion of the immune system by cancer cells [17]. 
Taken together, these pro-tumorigenic mechanisms are most prominently enabled by the development of 
genomic instability in malignant cells, generating mutations and chromosomal aberrations [17]. In the 
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course of molecular hepatocarcinogenesis, genomic aberrations start to occur randomly in pre-malignant 
lesions and further increase extensively in dysplastic nodules and HCCs [13]. Somatic mutations in cancer 
cell genomes include point mutations, insertions or deletions of DNA segments and chromosomal 
translocations, as well as copy number alterations. In case of viral infections exogenous DNA can be 
integrated in the genome, adding an additional mode how viruses such as HBV can contribute to 
carcinogenesis [18]. Molecular screenings of human HCCs showed mutations of different (driver) 
oncogenes and tumor suppressor genes such as TP53, c-MYC, CTNNB1 (β-catenin), TERT and COX2 
(cyclooxygenase 2) [2, 13, 19].  
The p53 tumor suppressor is a main coordinator of extra- and intracellular stress signals including DNA 
damage and induces a variety of cellular responses such as DNA damage repair, cell cycle arrest, 
senescence and apoptosis [20–22]. Following activation, p53 acts as transcription factor, thus trans-
activating or -repressing hundreds of different target genes or interacts with other proteins to modulate 
cellular signaling cascades and thereby mainly activates apoptosis, senescence or, if the damage is 
reversible, cell-cycle arrest  [20, 23–25]. Over 50% of human malignancies acquire mutations in the TP53 
gene or in genes that encode for proteins interfering with the p53 network, which highlights its 
outstanding significance in tumor biology [22, 26, 27]. The vast majority of cancer-related TP53 mutations 
affect the p53 DNA binding domain and therefore p53’s function as transcriptional activator [22]. 
Moreover, mutations in the TP53 locus are usually either accompanied by loss of heterozygosity in the 
course of tumor progression or the mutated proteins exert a dominant-negative behavior over the left 
wildtype allele [28–30]. Additionally, the p53 pathway can be inactivated via amplification and 
subsequently over-activation of p53-inhibitors (e.g. MDM2, MDMX) or binding to viral proteins. 
Controversially, gain-of-function mutations can transform p53 into a potent oncogene [20–22, 26, 31]. In 
conclusion, loss of p53 wild-type function is beneficial for (hepato-)carcinogenesis and tumor progression, 
enabling tumor cells to inactivate multiple tumor-suppressive responses by inactivation of one key protein. 
Next to mutations in p53, WNT/β-catenin signaling is among the most frequently altered pathways in HCC 
[32]. This pathway is usually involved in embryogenesis and tightly regulated during fetal liver 
development [5, 32]. Induction of the canonical WNT pathway triggers enrichment of β-catenin in the 
cytoplasm followed by translocation into the nucleus where β-catenin can act as transcription factor for 
genes involved in differentiation, proliferation and tumor initiation [32]. As WNT/β-catenin signaling is 
involved in embryonic development, activation of this pathway in HCC supports the above-mentioned 
stem cell model of hepatocarcinogenesis.  
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Additional to these somatic mutations, shortening of telomeres in combination with chronic liver disease 
and turnover of hepatocytes has been described to trigger genomic instability which further promotes HCC 
initiation. On the contrary, a strong increase in TERT expression and therefore reactivation of telomerase 
is a characteristic of HCC progression and was found in nearly all human HCCs [2, 19]. Next to molecular 
alterations, epigenetic changes, i.e. variations in the methylation of chromatin residues that subsequently 
alter gene expression, have been observed in different stages of hepatocarcinogenesis [18][2]. Altogether, 
HCCs show a broad heterogeneity in genomic alterations which ultimately affect multiple signaling 
pathways  [13].  
1.1.4 Surveillance, diagnosis and treatment options 
Since HCC is often diagnosed in late stages due to the lack of clinical symptoms, the European Association 
for the Study of the Liver (EASL-EORTC) and the American Association for the Study of Liver Diseases 
(AASLD) guidelines recommend surveillance of high risk patients by ultrasonography every six months [33–
35]. However, surveillance programs are controversially discussed due to their dependency on the 
ultrasonography operator, the question whether prognostic markers (e.g. α-fetoprotein) are suitable for 
early detection of HCC and the inconsistent results of different surveillance program meta-analyses [36].  
As surveillance, diagnosis is usually done using different imaging techniques and, if results are inconclusive, 
by additional biopsy analyses [36]. Tumor staging is pivotal for the choice of the appropriate treatment 
regime. Several different staging systems exist with the Barcelona Clinic Liver Cancer (BCLC) classification 
being the most effective for prognosis and selection of therapy [33, 37]. Depending on the stage of HCC at 
the point of diagnosis, different treatment options are implemented. Curative therapies include tumor 
resection, liver transplantation and local ablation (radiofrequency or ethanol injection), while 
transcatheter arterial chemoembolization (TRACE) and systemic therapies are applied in patients with 
intermediate and advanced HCCs [33, 38]. Far advanced HCC is untreatable and usually lethal within 3-6 
months. In this stage, patients only receive palliative care [33, 36]. 
The high mortality is partially due to resistance to established anti-cancer drugs, a lack of reliable 
biomarkers and the causal liver disease which limits chemotherapeutical treatment options [2]. Sorafenib 
is the first-line therapy for patients with advanced HCC and increases the average survival of patients from 
7.9 to 10.7 months with manageable side-effects [33, 39]. Sorafenib is an oral multi-kinase inhibitor that 
disables the Ras-Raf-MAP2K-MAPK pathway, thereby blocking angiogenesis, proliferation and migration 
and ultimately the resistance to apoptosis [40]. So far, Sorafenib, which was approved in 2008, has been 
the only systemic treatment for advanced HCC. In a recent study, Regorafenib, an oral multi-kinase 
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inhibitor used for the treatment of colorectal and gastrointestinal cancer, showed a further survival benefit 
in HCC patients that progressed under Sorafenib treatment and was approved as second-line therapy [41, 
42]. Other promising drug candidates tested in different studies as first-line treatments either did not 
improve overall survival or showed an adverse toxicity profile compared to Sorafenib [42].  
Intra-tumor heterogeneity, cell plasticity and resistance mechanisms put a limit on highly selective 
therapeutic approaches in HCC. Combined systemic treatments are often accompanied by high liver 
toxicity which is unfavorable in combination with the underlying chronic liver disease [38]. A deeper 
understanding of the molecular mechanisms that shape the malignant phenotype of HCC cells is critical to 
identify novel drug targets and will provide the basis for improved therapeutic approaches [43]. 
1.2 The nuclear transport system 
 
1.2.1 Nuclear import and export mechanisms  
The eukaryotic nucleus is separated from the cytoplasm by the nuclear envelope, thereby not only 
uncoupling transcription and translation, but also adding an additional mode of protein activity regulation 
[44–46]. To enable controlled transport in and out of the nucleus, protein channels, the nuclear pore 
complexes (NPC), are enclosed in the nuclear membrane. An average NPC is composed of roughly 30 
different proteins, most of them so-called nucleoporins (Nups, Figure 1.2), and has a molecular mass of 
approximately 125 MDa [44–47].  
 
Figure 1.2: Components of the nuclear transport system. Structure of the NPC and its sub-complexes. (B) List 
of nuclear import and export receptors (bold: bi-directional shuttling receptors). Reprinted and modified with 
permission from [48]. 
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Molecules smaller than 40 kDa (e.g. ATP) can diffuse freely through the NPCs, however, the transport of 
larger molecules (e.g. proteins, RNAs, ribosomal subunits) relies on an active transport system [46, 47, 49–
51]. The canonical nucleocytoplasmic transport of proteins is facilitated by interactions between the cargo 
molecule, nuclear transport receptors (NTRs; e.g. importins, exportins, karyopherins) and the small GTPase 
Ran [44, 46]. In order to be imported, proteins have to contain a specific sequence, the nuclear localization 
signal (NLS), whereas proteins for export are labeled by a nuclear export signal (NES) [44, 46]. Protein 
shuttling across the nuclear envelope requires the following steps: recognition of the cargo protein (i.e. 
the import or export signal) by a receptor, binding of the protein-receptor complex to the NPC, transition 
of the transport channel and eventually the recycling of the transport receptors [52]. Thereby, the 
transport rate is controlled by the RanGTPase and its regulators [46].  
Most proteins rely on nuclear transport receptors, mostly of the karyopherin superfamily, for their 
transport in and out of the nucleus. The mammalian karyopherin superfamily includes over 20 members, 
the so-called importins and exportins [46, 50], which have similar conformations although only having 
partial sequence identity [49]. There are two subclasses of importins: importin-α (karyopherin-α), an 
adaptor molecule that binds the cargo-NLS, and importin-β (karyopherin-β), which binds to the importin-
α-cargo-complex and leads the trimeric complex through the transport channel. After binding of RanGTP 
to importin-β, the transport complex dissociates and the cargo is released into the nucleoplasm. 
Eventually, both karyopherins are translocated back to the cytoplasm: importin-α binds to its export 
receptor CAS (cellular apoptosis susceptibility) and RanGTP, while the RanGTP-importin-β dimer passes 
the NPC independently (Figure 1.3 A) [46, 50]. 
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Figure 1.3: Nuclear import and export cycle. (A) Nuclear import: The adaptor protein importin-α (α, green) 
binds to the nuclear localization signal on the cargo protein (NLS protein, blue) and forms a trimer with 
importin-β (β, red). The complex passes the nuclear pore complex and enters the nucleus. After binding of 
RanGTP (purple) to importin-β, the complex dissociates, the cargo is released and the transport receptors are 
recycled to the cytoplasm [46, 50]. (B) Nuclear export: Proteins labeled with a nuclear export signal-specific 
sequence (NES protein, blue) are recognized by CRM1 (green). The protein-CRM1 complex binds to RanGTP 
(purple) via CRM1 and passes the NPC. In the cytoplasm, RanGTP is hydrolyzed to RanGDP (orange), the cargo 
is released and CRM1 is recycled to the nucleus. Reprinted with permission from [46]. 
 
Cargo proteins that have to be exported from the nucleus to the cytoplasm and contain a NES are 
recognized by a member of the karyopherin-β family, the export receptor CRM1 (chromosomal 
maintenance 1 or exportin-1). After binding of the cargo, CRM1 complexes with RanGTP and transits the 
nuclear pore. In the cytoplasm, RanGTP is hydrolyzed to RanGDP by RanGAP (RanGTPase-activating 
protein) and the export complex dissociates (Figure 1.3 B) [46].  
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Nuclear transport can be regulated either by modifications of the cargo, expression (rate) of the transport 
receptors or the number of the NPCs embedded in the nuclear envelope [46]. Karyopherin cargo proteins 
are involved in a wide range of cellular processes and adequate nuclear-cytoplasmic localization is pivotal 
for the execution of normal cell functions [51]. In cancer, the intracellular location of tumor suppressor 
and oncogenes shows a subcellular maldistribution promoting unrestricted cell growth [46]. 
1.2.2 Karyopherin-α2  
The karyopherin-α family comprises seven known members, one of them being karyopherin-α2 (KPNA2, 
importin-α subunit 1). KPNA2 is a 58 kDa protein containing an N-terminal karyopherin-β binding domain 
and a central region of ten armadillo repeats that mediates binding of the NLS as well as of CAS [50]. 
However, karyopherin-α can also bind to cargo proteins independently of karyopherin-β [46].  
KPNA2 mediates the nuclear import of various different cargo proteins involved in a broad range of cellular 
processes [49, 53]. Tumor-associated KPNA2 transport substrates include BRCA1, NBS1, E2F1 and the MRN 
complex which is crucial for DNA double-strand break repair [49, 54–57]. In addition to the nuclear import 
of cancer-related factors, several studies proved the overexpression of KPNA2 itself in tumor tissue (e.g. 
breast, bladder, liver and ovarian cancer) [58–62]. However, its functional role particularly in HCC remains 
incompletely understood. 
1.3 Microtubule dynamics 
1.4.1 Structure and function of microtubules  
Microtubules (MTs) are α-/β-tubulin heterodimers that are part of all eukaryotic cells and spatially 
structure the cytoplasm in non-dividing cells and thereby constitute the cytoskeleton. Besides their role in 
cell structure, MTs form the mitotic spindle apparatus during the process of mitosis, allowing chromosome 
segregation and orientation of the cleavage plane [63]. MTs polymerize by adding GTP-tubulin dimers to 
the MT end which is further stabilized by a GTP-tubulin enriched cap. MT growth and shrinkage is 
determined by MT polymerases and depolymerases as well as kinesins located at their ends. Loss of the 
cap induces rapid shrinkage (depolymerization), the so-called MT catastrophe [64]. MTs are polymerizing 
and depolymerizing constantly in a highly dynamic process that enables rapid reorganization of the 
cytoplasm [63] and is pivotal for tumor cell growth, migration and invasion [65]. 
1.4.2 Stathmin 
MT-interacting proteins act on the dynamic MT-turnover either by MT-stabilization or -destabilization [64]. 
Stathmin (STMN1; also oncoprotein 18, Op18) is a soluble, cytosolic phosphoprotein that destabilizes MTs 
during mitosis. In humans, it is encoded by the STMN1 gene [66]. Next to stathmin, the family comprises 
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three other members (stathmin 2-4) which are all involved in the regulation of MT stability [67]. Stathmin 
regulates MT dynamics by sequestering α/β-tubulin-dimers, thereby preventing the polymerization of 
MTs. Additionally, stathmin binds to MTs directly to promote their catastrophe. If stathmin gets 
phosphorylated, it is inactivated and mitotic spindles can assemble [68]. 
In normal tissue, stathmin is ubiquitously expressed, with the lowest levels found in the liver [69]. It was 
shown that stathmin is predominantly present in proliferating cells with a peak in S- and G2/M-phases 
[70]. Consequently, stathmin depletion promotes cell cycle arrest and apoptosis [71]. In human tumors 
(e.g. breast, lung, ovarian cancer and HCC) stathmin is frequently overexpressed and associated with 
metastasis and poor survival suggesting an involvement in cancer progression and dissemination [65, 66, 
72, 73]. Furthermore, experimental data demonstrate that RNAi-mediated protein silencing inhibits 
clonogenicity and migration and promotes apoptosis in different tumor entities in vitro, making stathmin 
a potential candidate for targeted therapy [65, 73, 74].  
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2 OBJECTIVES   
 
A deeper understanding of the molecular mechanisms that shape the malignant phenotype of HCC cells is 
critical to identify novel drug targets and will provide the basis for improved therapeutic approaches [43]. 
It was previously reported that members of the nuclear transport machinery are involved in 
protumorigenic processes in different tumor entities, however, several NTS-related mechanisms in (liver-) 
tumor biology remain poorly understood. Regulating the nuclear import of oncogenes and/or tumor 
suppressors, nuclear transport factors are pivotal mediators of (aberrant) gene expression in cancer  [48, 
51, 75]. Based on a previous report describing deregulation of nuclear transport factors in HCC [61], the 
nuclear import receptor KPNA2 was chosen for further investigation.   
Therefore, within this doctoral thesis, I aimed to: 
 Identify KPNA2 downstream targets in an unbiased approach using LC-MS/MS 
 Characterize the functional significance of KPNA2 in HCC 
 Characterize the functional implications of the identified KPNA2 downstream target stathmin 
 Elucidate the mechanisms by which KPNA2 regulates stathmin 
 Correlate the results obtained in vitro with the in vivo situation by analyzing data derived from   
HCC patient cohorts  
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3 MATERIALS 
3.1 Cell culture 
3.1.1 Cell lines 
The used cell lines are summarized in Table 3.1.  
Table 3.1: Cell lines: origin and cultivation media.  
Cell line Origin Cultivation medium Supplier 
Hep3B HCC MEM ATCC, LGC Standards, 
Wesel, Germany 
HepG2 hepatoblastoma RPMI ATCC, LGC Standards, 
Wesel, Germany 
HLE HCC DMEM JCRB, Tokyo, Japan 
HLF HCC DMEM JCRB, Tokyo, Japan 
HuH1 HCC DMEM JCRB, Tokyo, Japan 
HuH6 hepatoblastoma DMEM JCRB, Tokyo, Japan 
HuH7 HCC DMEM JCRB, Tokyo, Japan  
PLC/PRF/5 HCC DMEM ATCC, LGC Standards, 
Wesel, Germany 
Snu182 HCC RPMI ATCC, LGC Standards, 
Wesel, Germany 
Sk-Hep1 liver endothelial cells DMEM ATCC, LGC Standards, 
Wesel, Germany 
THLE-2 hepatocytes (SV40 
transformed) 
BEBM ATCC, LGC Standards, 
Wesel, Germany 
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3.1.2 Cell culture media and reagents 
All media, reagents and supplements used for cell cultivation and treatment are summarized in Table 3.2. 
Table 3.2: Cell culture media and reagents. 
Reagent Order number Supplier 
Media and supplements   
Bronchial Epithelial Cell Growth 
Basal Medium (BEBM) 
CC-3171 Lonza, Cologne, Germany 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
D5796 Sigma-Aldrich, Taufkirchen, 
Germany 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
D8537 Sigma-Aldrich, Taufkirchen, 
Germany 
Fetal Bovine Serum (qualified, 
heat inactivated) 
10500064 Thermo Fisher Scientific, 
Waltham, USA 
Opti-MEM® I Reduced Serum 
Medium 
31985047 Thermo Fisher Scientific, 
Waltham, USA 
Penicillin-Streptomycin Solution 
(10,000 units each) 
15140130 Thermo Fisher Scientific, 
Waltham, USA 
Roswell Park Memorial Institute 
1640 (RPMI 1640) 
R8758 Sigma-Aldrich, Taufkirchen, 
Germany 
Trypsin-EDTA solution T3924 Sigma-Aldrich, Taufkirchen, 
Germany 
Reagents   
Doxycycline hyclate D9891 Sigma-Aldrich, Taufkirchen, 
Germany 
Fugene® HD Transfection 
Reagent  
E2311 Promega, Mannheim, Germany 
Hepatocyte growth factor (HGF) 294-HG R&D, Minneapolis, USA 
Hexadimethrine bromide 
(Polybrene) 
H9268 Sigma-Aldrich, Taufkirchen, 
Germany 
Mitomycin C - Pharmacy, University Hospital 
Heidelberg, Heidelberg, 
Germany 
Nutlin-3a N6287 Sigma-Aldrich, Taufkirchen, 
Germany 
OligofectamineTM Transfection 
Reagent 
12252011 Thermo Fisher Scientific, 
Waltham, USA 
Puromycin P8833 Sigma-Aldrich, Taufkirchen, 
Germany 
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3.1.3 Small interfering RNAs 
All small interfering RNAs (siRNAs) used for transient gene knockdown are summarized in Table 3.3. 
Table 3.3: siRNAs used for protein depletion. Eurofins Genomics siRNAs were modified with a 3’-poly-T-tail. 
siRNA Sequence (5’-3’) Order number Supplier 
AllStars Neg. 
Control siRNA 
 1027280 QIAGEN, Hilden, 
Germany 
c-JUN#1 AAG AAC GUG ACA GAU GAG CAG SI00300580 QIAGEN, Hilden, 
Germany 
c-JUN#2 CCC GAG CUG GAG CGC CUG AUA SI03077599 QIAGEN, Hilden, 
Germany 
E2F1#1 AAC UCC UCG CAG AUC GUC AUC SI00300083 QIAGEN, Hilden, 
Germany 
E2F1#2 CAG AUC UCC CUU AAG AGC AAA SI03064775 QIAGEN, Hilden, 
Germany 
FBP-1#1 (AUA CAG AUA GCU CCU GAC A)TT  
 
 Eurofins Genomics, 
Ebersberg, Germany 
FBP-1#2 (GGC AGG AAC GGA UCC AAA U)TT  
 
 Eurofins Genomics, 
Ebersberg, Germany 
FBP-2#1 (GAG AUC AAC CGG AGA GCA A)TT   Eurofins Genomics, 
Ebersberg, Germany 
FBP-2#2 (CAG GAC GGA UCU CAG AAU A)TT  
 
 Eurofins Genomics, 
Ebersberg, Germany 
KPNA2#1  (AAU CUU ACC UGG ACA CUU U)TT  Eurofins Genomics, 
Ebersberg, Germany 
KPNA2#2 (UUC GUU AAG CUU AAU UGA GAA)TT  Eurofins Genomics, 
Ebersberg, Germany 
p53#1 (UGU UCC GAG AGC UGA AUG A)TT  Eurofins Genomics, 
Ebersberg, Germany 
p53#2 (AGA CCU AUG GAA ACU ACU U)TT  Eurofins Genomics, 
Ebersberg, Germany 
STMN1#1 (AGG CAA UAG AAG AGA ACA A)TT  Eurofins Genomics, 
Ebersberg, Germany 
STMN1#2 (AAG AGA AAC UGA CCC ACA A)TT  Eurofins Genomics, 
Ebersberg, Germany 
TFDP1#1 CAG AAC CUU AGU CCC GGG AAA SI00094654 QIAGEN, Hilden, 
Germany 
TFDP1#2 CAC AUU UGA AAU CCA CGA UGA SI03056858 QIAGEN, Hilden, 
Germany 
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3.2 Molecular cloning 
3.2.1 Reagents for molecular techniques 
All reagents used for methods of molecular biology (cloning, transformation etc.) are summarized in 
Table 3.4. 
Table 3.4: List of reagents used for molecular biological techniques. 
Reagent Order number Supplier 
Agarose 2267.4 Carl Roth, Karlsruhe, Germany 
Ampicillin Sodium Salt A9518 Sigma-Aldrich, Taufkirchen, 
Germany 
Dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich, Taufkirchen, 
Germany 
DNA Gel Loading Dye 6x R0611 Thermo Fisher Scientific, 
Waltham, USA 
DPN I (10 U/µL) ER1701 Thermo Fisher Scientific, 
Waltham, USA 
GelRed Nucleid Acid Gel Stain 41003 Biotium, Hayward, USA 
GeneRuler 1 kb DNA Ladder SM0314 Thermo Fisher Scientific, 
Waltham, USA 
Kanamycin sulphate T832.2 Carl Roth, Karlsruhe, Germany 
Phusion GC Buffer 5x F-519 Thermo Fisher Scientific, 
Waltham, USA 
Phusion DNA polymerase  
(2 U/µL) 
F-530L Thermo Fisher Scientific, 
Waltham, USA 
Proteinase K 59895 Thermo Fisher Scientific, 
Waltham, USA 
Tango Buffer 10x BY5 Thermo Fisher Scientific, 
Waltham, USA 
Ultra PureTM Distilled Water  10977-035 Thermo Fisher Scientific, 
Waltham, USA 
 
3.2.2 Primers for molecular cloning 
Primers used for cloning of KPNA2 and STMN1 Gateway vectors are summarized in Table 3.5. Cloning 
primers were obtained from Apara Bioscience (HPLC purified; Denzlingen, Germany). 
Table 3.5: Primers for Gateway cloning. Green: attB1/attB2 site; red: Kozak sequence. 
Name NCBI Accession 
numbers 
Sequences (5’-3’) 
KPNA2 NM_001320611.1 
NM_002266.3 
For: 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCATGTCCACCAACGAGA
ATG 
Rev:  
GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAAAAGTTAAAGGTCCCAG 
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3.2.3 Vectors for molecular cloning 
All vectors used for molecular cloning are summarized in Table 3.6. 
Table 3.6: Vectors for cloning. Vector backbones, entry and expression vectors. 
Vector Technology Comment 
Vector backbones   
pDonor201 Gateway entry vector Kindly provided by  
Dr. Stefan Pusch 
pDest26-N-FLAG Gateway destination vector Kindly provided by  
Dr. Stefan Pusch 
pDest26-N-HA Gateway destination vector Kindly provided by  
Dr. Stefan Pusch 
pcDNA3   
Entry clones   
pDONR201-E2F1 Gateway cloning +/- stop codon; kindly provided 
by Dr. Stefan Pusch 
pDonor201-KPNA2 Gateway cloning Silent mutation 
pDonor255-TFDP1 Gateway cloning Addgene (#70627); kindly 
provided by  
Dr. Dominic Esposito 
Expression vectors   
pCMVTNT-T7-KPNA2  Addgene (#26678); kindly 
provided by Dr. Bryce Paschal 
pDest26-N-FLAG-E2F1 Gateway cloning  
pDest26-N-HA-E2F1 Gateway cloning  
pDest26-N-HA-KPNA2 Gateway cloning  
pDest26-N-FLAG-TFDP1 Gateway cloning  
pDest26-N-HA-TFDP1 Gateway cloning  
 
3.2.4 Bacterial strains 
Bacteria used for transformation and vector production are summarized in Table 3.7. 
Table 3.7: Bacteria for vector production. 
Bacterial strain Supplier 
One ShotTM Mach1TM T1 Phage-Resistant Chemically 
Competent E. coli 
Thermo Fisher Scientific, Waltham, USA 
One ShotTM ccdB Survival™ 2 T1R Competent Cells  Thermo Fisher Scientific, Waltham, USA 
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3.2.5 Sanger sequencing 
Primers for sanger sequencing are summarized in Table 3.8.  
Table 3.8: Primers used for sanger sequencing. 
Name Application Sequence (5’-3’) 
pDONR for pDonor forward primer TAACGCTAGCATGGATCTC 
pDONR rev pDonor reverse primer GCAATGTAACATCAGAGAT 
CMV for pDest forward primer CGCAAATGGGCGGTAGGCGTG 
T7 pDest reverse primer TAATACGACTCACTATAGG  
 
3.3 Primers for semi-quantitative real-time PCR 
All primers used for semi-quantitative real-time PCR were obtained from Thermo Fisher Scientific 
(Waltham, USA) or Apara Bioscience (Denzlingen, Germany) and are summarized in Table 3.9.  
Table 3.9: List of primers used for semi-quantitative real-time PCR. 
Name NCBI Accession number(s) Sequences (5’-3’) 
Human genes   
E2F1 NM_005225 For: GCCAAGAAGTCCAAGAACCAC 
Rev: CGCAGCTGCGTAGTACAGATATTC 
KPNA2 NM_001320611 
NM_002266 
For: AGGAAAACCGCAACAACCAG 
Rev: ACCAGCCCGGATTATGTTGT 
RPL32 NM_000994 
NM_001007073 
NM_001007074 
For: TTCCGGTCCACAACGTCAAG 
Rev: TGTGAGCGATCTCGGCAC 
STMN1 NM_001145454 
NM_005563 
NM_203399 
NM_203401 
For: TGCAGAATACACTGCCTGTC 
Rev: AGGCACGCTTCTCCAGTTCT 
TFDP1 NM_007111 For: GTAGGAAGCCCACACACCCCCA 
Rev: GAAATGCCGTAGGCCCTTGCCA 
Murine genes   
Actb NM_007393 For: GCTTCTTTGCAGCTCCTTCGT  
Rev: ACCAGCGCAGCGATATCG  
Gapdh NM_008084 For: TGTCCGTCGTGGATCTGAC  
Rev: CCTGCTTCACCACCTTCTTG  
Hprt NM_013556 For: TCCTCCTCAGACCGCTTTT  
Rev: CCTGGTTCATCATCGCTAATC  
Ppia NM_008907 For: GCATACAGGTCCTGGCATCT  
Rev: AGCTGTCCACAGTCGGAAAT  
Tbp NM_013684 For: TTGTCTGCCATGTTCTCCTG  
Rev: CAGGGTGATTTCAGTGCAGA  
Stmn1 NM_019641 For: GACCTTTCCCTGGAGGAAATCC 
Rev: GAAGTTGTTGTTCTCCTCGATGGC 
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Primers used for quantification of precipitated DNA following chromatin immunoprecipitation (ChIP) were 
obtained from Thermo Fisher Scientific (Waltham, USA) and are summarized in Table 10. 
Table 3.10: List of primers used for quantification of precipitated DNA. BS: binding site. 
Name  Sequence (5’-3’) 
STMN1 Promoter Negative Control BS For: CACAACCCAGGAGGGAAACAG 
Rev: CACCCTGTTCTGACTTGGATGC 
CDC2-STMN1 Promoter BS For: CGCCCTTTCCTCTTTCTTTC 
Rev: ATCGGGTAGCCCGTAGACTT 
E2F1-STMN1 Promoter BS1 For: ACCCACCTGCTCAGTCCG 
Rev: CGGGTCTGTTGGTGCTCAGAG 
E2F1-STMN1 Promoter BS2 For: CTCCCCGCGCCTTTTCGAATC 
Rev: GGCTCCGGGGTGTTGAGTTC 
 
3.4 Antibodies 
All antibodies used for western blot, immunoprecipitation and immunohistochemistry are summarized in 
Table 3.11.  
Table 3.11: List of used antibodies. WB: western blot; ChIP: chromatin immunoprecipitation; CoIP: 
co-immunoprecipitation; IHC: immunohistochemistry. 
Antibody Species Dilution Order number Supplier 
Primary antibodies     
Actin (Clone C4) mouse 1:10,000 (WB)  69100 MP Biomedicals, 
Heidelberg, Germany 
ATF-2 (N-96) rabbit 1:200 (WB) sc-6233 Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
β-tubulin mouse 1:1000 (WB) 556321 Becton, Dickinson and 
Company, Franklin 
Lakes, USA 
E2F-1 (ChIP Ab+) mouse 3 µg (ChIP) 17-10061 Millipore, Burlington, 
USA 
E2F-1 (C-20) 
 
rabbit 1:300 (WB) sc-193 Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
GFP rabbit 1:2000 (WB) G1544 Sigma-Aldrich, 
Taufkirchen, Germany 
IgG1 mouse IP control sc-2025 Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
KPNA2 rabbit 1:2000 (WB), 
1:50 (IHC) 
 
ab84440 Abcam, Cambridge, UK 
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Antibody Species Dilution Order number Supplier 
Primary antibodies     
KPNA2 mouse 2 µg (CoIP) 610485 Becton, Dickinson and 
Company, Franklin 
Lakes, USA 
PARP rabbit 1:500 (WB) 9542 Cell Signaling 
Technology, Frankfurt 
am Main, Germany 
p53 mouse 1:5000 (WB) 554293 Becton, Dickinson and 
Company, Franklin 
Lakes, USA 
Phospho-Stathmin 
(Ser38; D19H10) 
rabbit 1:1000 (WB) 4191 Cell Signaling 
Technology, Frankfurt 
am Main, Germany 
Stathmin 1 (EP1573Y) rabbit 1:2000 (WB),  
1:50 (IHC) 
ab52630 Abcam, Cambridge, UK 
TFDP1 mouse 1:200 (WB) AM00404AF-N Acris, Herford, Germany 
TFDP1 rabbit 1:500 (WB) ab186831 Abcam, Cambridge, UK 
Vinculin mouse 1:5000 (WB) V9131 Sigma-Aldrich, 
Taufkirchen, Germany 
Secondary antibodies     
IRDye 680LT  
anti-mouse 
donkey IgG 1:10,000 (WB) 926-68022 LI-COR Bioscience, Bad 
Homburg, Germany 
IRDye 680LT  
anti-rabbit 
donkey IgG 1:10,000 (WB) 926-68023 LI-COR Bioscience, Bad 
Homburg, Germany 
IRDye 800CW  
anti-mouse 
donkey IgG 1:10,000 (WB) 926-32212 LI-COR Bioscience, Bad 
Homburg, Germany 
IRDye 800CW  
anti-rabbit 
donkey IgG 1:10,000 (WB) 926-32213 LI-COR Bioscience, Bad 
Homburg, Germany 
 
3.5 Chemicals and reagents 
All used chemicals and reagents are summarized in Table 3.12. 
Table 3.12: Chemicals and reagents. 
Chemical/reagent Order number Supplier 
Agarose 2267.4 Carl Roth, Karlsruhe, Germany 
Albumin Bovine, DNase/RNase-
Free (BSA) 
11967.09 SERVA, Heidelberg, Germany 
Ammonium persulfate (APS) 1610700 Bio-Rad, Munich, Germany 
Boric acid (≥ 99.8%) 6943.1 Carl Roth, Karlsruhe, Germany 
Cell Lysis Buffer 10x 9803 Cell Signaling Technology, 
Frankfurt am Main, Germany 
Cristal violet C-3886 Sigma-Aldrich, Taufkirchen, 
Germany 
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Chemical/reagent Order number Supplier 
Dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich, Taufkirchen, 
Germany 
dNTP Mix (10 mM each) R0192 Thermo Fisher Scientific, 
Waltham, USA 
Dynabeads Protein G 10004D Thermo Fisher Scientific, 
Waltham, USA 
Ethanol 32205 Sigma-Aldrich, Taufkirchen, 
Germany 
Fisher’s EZ-RunTM Pre-Stained 
Rec Protein Ladder  
BP3603-506 Thermo Fisher Scientific, 
Waltham, USA 
Glycine LC-4522.2 Labochem, Heidelberg, 
Germany 
Guava® Cell Cycle Reagent 4500-0220 Merck, Darmstadt, Germany 
Isopropanol  190764 Sigma-Aldrich, Taufkirchen, 
Germany 
Milk powder T145.2 Carl Roth, Karlsruhe, Germany 
Phenylmethanesulfonylfluoride 
(PMSF) 
P7626 Sigma-Aldrich, Taufkirchen, 
Germany 
PhosSTOP 10x 4906845001 Roche, Mannheim, Germany 
Protease-Inhibitor Mix G 1000x  39101 SERVA, Heidelberg, Germany 
Protein Assay Dye Reagent 
Concentrate (Bradford reagent) 
500-0006 Bio-Rad, Munich, Germany 
PrimaQUANT qPCR-CYBR-Green-
MasterMix-high-ROX 
SL-9912 Steinbrenner, Heidelberg, 
Germany 
Random Hexamer Primer SO142 Thermo Fisher Scientific, 
Waltham, USA 
Salmon sperm DNA solution 10605543 Thermo Fisher Scientific, 
Waltham, USA 
SOC Outgrowth Medium B9035 New England Biolabs, Frankfurt, 
Germany 
TEMED 2367.3 Carl Roth, Karlsruhe, Germany 
   
Tris(hydroxymethyl)-
aminomethane (TRIS) 
4855.2 Carl Roth, Karlsruhe, Germany 
Tween 20 9127.1 Carl Roth, Karlsruhe, Germany 
Ultra PureTM Distilled Water  10977-035 Thermo Fisher Scientific, 
Waltham, USA 
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3.6 Buffers 
All prepared buffers and solutions are summarized in Table 3.13. 
Table 3.13: Buffers and solutions. 
Name Formula 
Borate buffer (pH 8.8; blotting buffer) 20 mM Boric acid, 1.27 mM EDTA  
Crystal violet staining solution 1% Crystal violet, 25% Methanol 
Glycine solution (pH 2.8) 50 mM Glycine 
IP wash buffer 100 mM Tris pH 8.5, 500 mM LiCl, 1% Igepal CA 630, 1% 
Na-Deoxycholate  
Laemmli Buffer (4x) 250 mM Tris-HCl pH 6.8, 8% SDS, 40% Glycerol,  
0.04% Bromophenol blue, 100 mM DTT  
LB agar 1.5% Agar in LB medium 
LB medium (pH 7) 1% Tryptone, 0.5% yeast extract, 1% NaCl  
Lysis buffer (pH 7.4; CoIP) 50 mM Tris HCl pH 7.4, 0.25% Sodium deoxycholate,  
150 mM NaCl, 1 mM EDTA, 1% NP-40  
Phosphate buffered saline (PBS) 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4x2H2O,  
1.8 mM KH2PO4  
PBST 0.02% Tween-20 in PBS 
Running buffer (SDS-PAGE) 25 mM Tris, 192 mM Glycine, 0.1% SDS  
TAE buffer (pH 8.0) 40 mM Tris-Acetate, 1 mM EDTA 
Talianidis buffer (ChIP elution) 70 mM Tris pH 8, 1 mM EDTA, 1.5% SDS 
TE buffer 70 mM Tris pH 8, 1 mM EDTA  
Tris buffered saline (pH 7.6; TBS) 20 mM Tris-HCl, 140 mM NaCl  
TBST 0.1% Tween-20 in TBS 
 
3.7 Kits 
All kits used for mycoplasma tests, cellular fractionation, RNA isolation and molecular biology assays are 
summarized in Table 3.14. 
Table 3.14: List of used kits. 
Kit Order number Supplier 
MycoAlertTM Plus Mycoplasma Detection 
Kit 
LT07 Lonza, Cologne, Germany 
NE-PER Nuclear and Cytoplasmic 
Extraction Reagents 
78833 Thermo Scientific, Rockford, USA 
NucleoBond® Xtra Maxi EF 740424 Macherey-Nagel, Dueren, Germany 
NucleoSpin® Gel and PCR Clean-up 740609 Macherey-Nagel, Dueren, Germany 
NucleoSpin® Plasmid 740588 Macherey-Nagel, Dueren, Germany 
NucleoSpin® RNA 740955 Macherey-Nagel, Dueren, Germany 
PureYieldTM Plasmid Midiprep System A2495 Promega, Mannheim, Germany 
Quick Western Kit – IRDye® 680 RD 926-68100 LI-COR Bioscience, Bad Homburg, 
Germany 
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3.8 Equipment and devices 
All used equipment and devices are summarized in Table 3.15. 
Table 3.15: List of used equipment and devices. 
Equipment Supplier 
General equipment  
12-Tube magnet QIAGEN, Hilden, Germany 
Amersham Protran nitrocellulose membrane, 0.45 µM GE Healthcare, Buckinghamshire, UK 
Mini PROTEAN Multi casting chamber  Bio-Rad, Munich, Germany 
Mini PROTEAN 3 Cell SDS-gel electrophoresis system Bio-Rad, Munich, Germany 
Mini Trans-Blot Cell Bio-Rad, Munich, Germany 
Mr. FrostyTM Freezing Container Thermo Fisher Scientific, Waltham, USA 
Neubauer Counting Chamber (improved) Brand, Frankfurt, Germany 
Electric devices  
AlphaImagerTM MultiImage Light Cabinet Biozym, Hessisch Oldendorf, Germany 
BIOWIZARD Silver Line safety cabinet Ewald, Bad Nenndorf, Germany 
Compact Shaker KS 15 control and Incubator Hood TH 15  Edmund Bühler GmbH, Hechingen, 
Germany  
FLUOstar Omega microplate reader BMG Labtech, Ortenberg, Germany 
Guava easyCyte flow cytometer EMD Millipore, Darmstadt, Germany 
INCOmed CO2 incubator Memmert, Schwabach, Germany 
Incubator (Bacteria) Memmert, Schwabach, Germany 
Labnet Spectrafuge Mini centrifuge Sigma-Aldrich, Taufkirchen, Germany 
Megafuge 16R centrifuge Thermo Fisher Scientific, Waltham, USA 
Mikro 200R centrifuge Hettich, Tuttlingen, Germany 
NanoDrop ND-1000 Thermo Fisher Scientific, Waltham, USA 
Odyssey Sa Infrared Imaging System LI-COR Bioscience, Bad Homburg, 
Germany 
Orbital shaker DOS-10L neoLab, Heidelberg, Germany 
Overhead rotator RM-2M neoLab, Heidelberg, Germany 
pH meter Microprocessor pH 210 Hanna Instruments, Voehringen, Germany 
Photometer Eppendorf, Hamburg, Germany 
Power supply EV231 Consort, Turnhout, Belgium 
PTC-200 PCR Cycler Bio-Rad, Munich, Germany 
S-4000 Sonicator Qsonica, Newton, USA 
Secuflow fume hood Waldner, Wangen, Germany 
Scale Kern, Balingen-Frommern, Germany 
StepOnePlusTM Real-Time PCR Applied Biosystems, Darmstadt, Germany 
Thermomixer compact Eppendorf, Hamburg, Germany 
Tube roller CAT RM5 neoLab, Heidelberg, Germany 
Universal 32R centrifuge Hettich, Tuttlingen, Germany 
Vortexer neoLab, Heidelberg, Germany 
Microscopes   
Axiovert 25  Zeiss, Oberkochen, Germany 
CKX31 (inverted microscope) Olympus, Hamburg, Germany 
CKX41 (inverted microscope) Olympus, Hamburg, Germany 
ORCA-R2 Camera controller Hamamatsu, Hersching, Germany 
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3.9 Software 
All used software is summarized in Table 3.16. 
Table 3.16: List of used software. 
Software Provider 
ApE v2.0.47 www.biologylabs.utah.edu/jorgensen/wayned/ape  
CellSens Dimension Olympus, Hamburg, Germany 
Fiji www.fiji.sc 
GraphPad Prism 6 GraphPad Software, San Diego, USA 
IBM SPSS Statistics 24.0 IBM, Ehningen, Germany 
Image Studio v3.1.4 LI-COR Bioscience, Bad Homburg, Germany 
InCyteTM FACS Software EMD Millipore, Darmstadt, Germany 
StepOne v2.3 Applied Biosystems, Darmstadt, Germany 
ZEN 2012 v8.0 Zeiss, Oberkochen, Germany 
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4 METHODS 
4.1 Cell culture methods 
4.1.1 Cell cultivation 
Cells were cultured in the media described in table 3.1 supplemented with 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin in an incubator at 37°C in an atmosphere containing 5% CO2. Cells were 
maintained on 10 cm cell culture dishes and split twice a week in a ratio according to their growth behavior. 
Cell culture supernatants were tested twice a year for mycoplasma contamination. 
4.1.2 Cryoconservation of cell lines 
For long-time storage, cells were trypsinized from sub-confluent 10 cm dishes, centrifuged to remove 
trypsin-EDTA (110 x g, 5 min) and resuspended in cryomedium containing 10% DMSO, 20% FCS and 70% of 
the respective growth medium. For freezing of cryogenic vials, a Mr.FrostyTM freezing container was used 
to freeze cells with a cooling rate of -1°C/min. For long term storage, cryoconserved cells were stored in a 
liquid nitrogen tank. To thaw cryo-conserved cells, warm growth medium was added to the cryogenic vials 
and the cell/cryomedium mixture was resuspended in growth medium. Cells were centrifuged as described 
above to remove DMSO and plated on a 10 cm dish. 
4.1.3 Seeding of cell lines 
Cells were seeded one day prior to the start of experiments. Cells were trypsinized, centrifuged to remove 
trypsin-EDTA (110 x g, 5 min), resuspended in growth medium and counted using an improved Neubauer 
chamber. Different cell number were seeded depending on the cell line, cell size, growth rate and type of 
experiment. The used cell numbers are summarized in Table 4.1. 
Table 4.1: Cell numbers seeded for different experiments. 
Cell line 12-well plate 6-well plate 6 cm dish 10 cm dish 
HepG2 - 250,000 - - 
HLE 35,000 40,000 25,000 (KPNA2 
siRNA treatment) 
70,000 (KPNA2 
siRNA treatment) 
HLF - 30,000 - - 
HuH6 - 300,000 - - 
HuH7 150,000 - - - 
PLC - 250,000 - - 
Snu182 - 60,000 (96 h) 
70,000 (48 h) 
80,000 (KPNA2 
siRNA treatment) 
- 
Sk-Hep1 - 150,000 - - 
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4.1.4 Transient protein depletion using small interfering RNAs 
For small interfering RNA (siRNA)-mediated gene knockdown cells were seeded onto 12-well or 6-well 
plates or 6 cm dishes the day prior to transfection. The day of transfection, cells were washed once and 
covered with 800 µL (6-well plates) or 1.6 mL (6 cm dishes) Opti-MEM. All siRNAs are summarized in Table 
3.3 and used at a final concentration of 50 nM with the exception of siRNAs directed against FBP-1 and 
FBP-2 (20 nM). For replication of experiments in the cell line Snu182, two siRNAs targeting the same gene 
were pooled (25 nM/siRNA). The QIAGEN AllStars Duplex served as control. Oligofectamine was used as 
transfection reagent. The transfection protocol is summarized in Table 4.2. Solution A and B were 
incubated at ambient temperature for 10 min, combined and incubated for another 10 min before they 
were added dropwise to the wells/dishes.  
Table 4.2: Protocol for siRNA transfection. 
Reagent 12-well plates 6-well plates 6 cm dishes 
Solution A    
Opti-MEM 90 µL 180 µL 360 µL 
siRNA/AllStars (20 µM) 1.25 µL 2.5 µL 5 µL 
Solution B    
Opti-MEM 7.5 µL 15 µL 30 µL 
Oligofectamine 1.5 µL 3 µL 6 µL 
 
Four hours after siRNA-treatment 0.5 mL (12-well plates), 1 mL (6-well plates) or 2 mL (6 cm dishes) of 
growth medium was added, 24 h after transfection the medium was completely exchanged. Cells were 
harvested 48-96 h after transfection for protein or RNA isolation. 
4.1.5 Transient protein overexpression 
For transient overexpression of proteins 0.5 or 1 µg of the respective plasmid DNA were mixed in a ratio 
of 1:3 with Fugene HD Reagent, added to Opti-MEM and incubated for 15 min at ambient temperature. 
Following incubation, the DNA/Fugene/Opti-MEM mixture was added dropwise to the cells. The vector 
backbone served as a control. If not mentioned otherwise, cells were harvested 24 h after transfection. 
4.1.6 Treatment with Nutlin-3a 
Nutlin-3a was used to induce p53 in liver cancer cell lines harboring wildtype p53. Nutlin-3a was resolved 
in DMSO to concentrations of 20 mM, respectively. Therefore, DMSO served as control in the subsequent 
experiments. For cell treatment, Nutlin-3a was diluted in growth medium to a final concentration of 
10 µM. 
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4.2 Molecular biological methods 
4.2.1 Gateway cloning 
To clone vectors for KPNA2 and stathmin overexpression, the Gateway Cloning System was used. attB-
flanked primers (Table 3.5) for the respective inserts and Gateway recombination were used to amplify 
the CDS sequences of the two genes from cDNAs obtained from HLE whole cell lysates. PCR was performed 
according to the manufacturer’s protocol using a gradient PCR with annealing temperatures around the 
primer melt temperatures. The used master mix is summarized in Table 4.3.  
Table 4.3: Master mix for Gateway gradient PCR. 
Reagent Volume 
cDNA 15 ng 
dNTP Mix (10 mM) 1 µL 
Forward primer (10 µM) 2.5 µL 
Reverse primer (10 µM) 2.5 µL 
5x Phusion GC Buffer 10 µL 
Phusion DNA Polymerase 1 µL 
dH2O ad 50 µL 
 
The conditions used for Gateway gradient PCR are summarized in Table 4.4. 
Table 4.4: PCR program for Gateway gradient PCR. 
PCR step Temperature Time Cycles 
Initial denaturation 98°C 30 sec 1 
Denaturation 98°C 30 sec 
30 
Annealing Primer dependent 
gradient 
30 sec 
Elongation 72°C 30 sec/kb template 
DNA 
Final elongation 72°C 10 min 1 
Hold step 4°C ∞ 1 
 
PCR products were separated by agarose gel electrophoresis. Therefore, 1.5% agarose was dissolved in 
TAE buffer and GelRed Nucleid Acid Gel Stain was added for UV light-based DNA detection. The PCR 
products were mixed with loading dye and pipetted into the wells of the solidified gel next to the 
GeneRuler 1 kb DNA ladder. Electrophoresis was performed for 1-2 h at 65-120 V. DNA was visualized 
using the AlphaImager gel documentation system and fragments consistent with the expected insert size 
were isolated from the gel. DNA was purified using the NucleoSpin® Gel and PCR Clean-up Kit as described 
in the manufacturer’s protocol.  
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In a next step, the respective PCR products were sub-cloned into pDONR201, which was used as entry 
vector, by BP reaction. Therefore, 75 ng of PCR product were mixed with 150 ng pDONR201 plasmid and 
1 µL BP Clonase II enzyme mix and adjusted to a final volume of 5 µL with TE buffer. The BP reaction was 
performed at 25°C for 2 h until the reaction was stopped by addition of 0.5 µL Proteinase K and incubation 
at 37°C for 10 min. For recombination of the insert from the pDONR201 entry clone into the destination 
vector, LR reaction was performed. In brief, 75 ng of the entry clone were mixed with 150 ng of the 
respective destination vector (i.e. pDest26, see Table 3.6) and 1 µL LR Clonase II enzyme mix and adjusted 
to a final volume of 5 µL with TE buffer. The LR reaction was incubated at 25°C overnight and inactivated 
using Proteinase K as described above.  
4.2.2 Bacterial transformation and plasmid isolation 
For the following transformation 50 µL of One ShotTM Mach1TM T1 Phage-Resistant Chemically Competent 
E. coli were carefully mixed with 5 µL of the plasmid obtained from BP or LR reactions and incubated on 
ice for 30 min. After a heat shock for 1 min at 42°C was performed, bacteria were incubated for 2 min on 
ice and 150 µL SOC Outgrowth Medium was added. Transformed bacteria were incubated for 1 h at 37°C 
while shaking and plated to selective agar plates depending on their respective resistance gene (Ampicillin 
or Kanamycin, 50 µg/mL). Plates were incubated overnight at 37°C. For transformation of vector 
backbones One ShotTM ccdB Survival™ 2 T1R Competent Cells were used to enable bacterial survival in 
presence of the ccdB site integrated into the plasmid.  
For expansion, single colonies were picked, resuspended in antibiotics-containing LB medium (50 mg/mL) 
and shaken overnight at 37°C. Depending on the used LB medium volume, the NucleoSpin® Plasmid, the 
PureYieldTM Plasmid Midiprep or the NucleoBond® Xtra Maxi EF kit was used for plasmid isolation 
according to the manufacturer’s protocol. For long-term storage, 30% glycerol was added to bacterial 
suspensions and bacteria were snap-frozen and stored at -80°C.  
4.2.3 Sequencing 
To verify the sequence of cloned vectors, sanger sequencing was carried out by Microsynth SeqLab 
(Goettingen, Germany) and results were compared to CDS and vector backbone sequences using the 
software ApE. 
4.2.4 Isolation of total RNA and cDNA synthesis 
The NucleoSpin RNA kit was used for isolation of total RNA. Cells were scraped in buffer RA1 supplemented 
with 1% β-mercaptoethanol and RNA was isolated according to the manufacturer’s protocol. The 
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concentration of isolated RNA per samples was quantified using a spectrophotometer and 1 µg of RNA 
was used for cDNA synthesis. The master mix for cDNA synthesis is summarized in Table 4.5. 
Table 4.5: Master mix for cDNA synthesis. 
Reagent Volume 
RNA 1 µg 
dH2O Ad 12 µL 
dNTP Mix (10 mM) 2 µL 
Random Hexamer Primer (100 µM) 1 µL 
Addition after initial denaturation  
Buffer RT 5x 4 µL 
ReverseAid H Minus RT 1 µL 
 
The PCR settings used for cDNA synthesis are summarized in Table 4.6. After the initial denaturation, the 
PCR program was paused and 5x Buffer RT was added. 5 min later, the program was put on hold a second 
time for ReverseAid H Minus RT addition.  
Table 4.6: PCR program for cDNA synthesis. 
PCR step Temperature Time 
Initial denaturation 75°C 5 min 
RevertAid activation 25°C 15 min 
dNTP annealing 
RevertAid inactivation 
42°C 
70°C 
1 h 
10 min 
Hold step 4°C ∞ 
 
Readily synthesized cDNA was diluted 1:80 to a final concentration of 0.625 ng/µL and stored at -20°C until 
further use.  
4.2.5 Semi-quantitative real-time PCR 
Semi-quantitative real-time PCR (qPCR) was performed to quantify mRNA expression levels using SYBR 
Green technology. The used primers are summarized in table 3.9. Forward and reverse primers were 
diluted in dH2O to a concentration of 10 µM per primer and used as a primer mix. Samples were analyzed 
in technical duplicates. The qPCR master mix is listed in Table 4.7.  
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Table 4.7: Master mix for qPCR. 
Reagent Volume 
cDNA 1.25 ng 
Primer mix (10 µM/primer) 0.8 µL 
CYBR-Green-MasterMix-high-ROX 5 µL 
dH2O ad 10 µL 
 
The qPCR settings are summarized in Table 4.8. Following signal quantification, the melt curve was 
measured to ensure the quality of the method. qPCR was performed using a StepOnePlusTM Real-Time PCR 
device. 
Table 4.8: qPCR program and melt curve. 
PCR step Temperature Time Cycles 
qPCR    
Initial denaturation 95°C 15 min 1 
Denaturation 95°C 15 sec 
40 Annealing/elongation/ 
fluorescence detection 
60°C 1 min 
Melt curve    
Denaturation 95°C 15 sec 
1 Annealing 60°C 30 sec Dissociation 60-95°C 0.5°C/5 sec 
Denaturation 95°C 15 sec 
 
To increase comparability of experiments, the threshold for ct-values was manually adjusted to 0.4 in all 
analyses. If not mentioned otherwise, RPL32 was used as reference gene. For analysis of murine tissue 
samples, five reference genes were measured and normalized using the GENORM algorithm. mRNA 
expression was calculated relative to the control sample using the comparative ΔΔCt method as described 
by Livak et al. [76]. 
4.2.6 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) assay was performed to study binding of proteins to regulatory 
DNA regions. To study binding of E2F1 to the STMN1 promoter, cells were seeded onto 15 cm dishes. The 
next day, protein and DNA were crosslinked by incubation of cells with 1% formaldehyde/PBS for 15 min 
followed by a quenching step with 125 mM glycine for 5 min and two washing steps with cold PBS. 
Subsequently, cells were harvested in 1 mL RIPA buffer (supplemented with protease inhibitor) and 
sonicated (2x 30 sec, power level 1.5, amplitude 15) to fragment genomic DNA to a size of 200-300 bp. Cell 
lysates were then centrifuged (18,000 x g, 4°C) for 15 min to remove cell debris. The protein concentration 
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of the supernatant was quantified using Bradford assay and adjusted to 1 mg/mL with RIPA buffer. For 
preclearing, 30 µL of pre-washed Dynabeads Protein G were added to every sample and rotated for 1.5 h 
at 4°C. Simultaneously, 50 µL pre-washed Dynabeads Protein G were blocked in salmon sperm DNA/BSA 
while rotating for 1.5 h at 4°C. Following preclearing, the Dynabeads were removed from the samples using 
a magnetic rack. The blocked Dynabeads were washed with RIPA buffer and added to the precleared 
samples together with 2 µg of the respective IP-antibody (control: IgG; see table 3.11). Samples were 
incubated overnight while rotating at 4°C. The next day, samples were washed as follows: 
 2x with 500 µL RIPA buffer (while rotating, 5 min, 4°C) 
 4x with 500 µL IP wash buffer (while rotating, 5 min, 4°C) 
 2x with 500 µL RIPA buffer (while rotating, 5 min, 4°C) 
 2x with 500 µL TE buffer 
Subsequently, Dynabeads were resuspended in 100 µL TE buffer and binding of the protein-DNA 
complexes to the Dynabeads was reversed by addition of 200 µL Talianidis elution buffer and incubation 
for 10 min at 65°C. In a next step, the supernatant was removed from the Dynabeads and the protein-DNA 
crosslink was reversed by addition of 13 µL of 4 M NaCl and incubation for 5 h at 65°C. DNA was purified 
using the NucleoSpin® Gel and PCR Clean-up Kit according to the manufacturer’s protocol.  
ChIP primers (table 3.10) were designed according to sequences obtained from publicly available ChIP-Seq 
datasets following E2F1 precipitation. As a negative control, a random sequence upstream of the predicted 
binding sequence was additionally quantified. Precipitated DNA was quantified using qPCR relative to the 
respective IgG control IP. 
4.3 Protein analytical methods 
4.3.1 Isolation of total protein 
For total protein isolation cells were washed twice with cold PBS and scraped in 30-100 µL 1x cell lysis 
buffer supplemented with protease and phosphatase inhibitors. Tubes containing the lysates were snap-
frozen in liquid nitrogen to enhance cell membrane disruption. Protein lysates were then centrifuged at 
18,000 x g for 10 min at 4 °C to pellet cell debris and the supernatant was used for further analyses.  
Bradford reagent was used for quantification of total protein concentrations. In a photometer cuvette, 
625 µL 1x Bradford reagent was added to 11.25 µL dH2O and 1.25 µL sample. After 5 min of incubation at 
ambient temperature, the optical density was measured at 595 nm using a photometer. Protein 
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concentration was calculated using a formerly established BSA standard curve. Protein samples were 
stored at -20°C until further usage.  
4.3.2 SDS-polyacrylamide gel electrophoresis and western blotting 
For semi-quantitative protein analysis, samples were separated using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Gels were prepared as described in Table 4.9.  
Table 4.9: SDS-PAGE gel preparation protocol. Volumes equal one gel (10 mL). 
Reagent 5% Stacking gel 8% Separating gel 12% Separating gel 
dH2O 6.8 mL 4.6 mL 3.3 mL 
30 % Acrylamide/Bis Solution (29:1) 1.7 mL 2.7 mL 4 mL 
1.5 M Tris-HCL (pH 8.8) - 2.5 mL 2.5 mL 
1 M Tris-HCL (pH 6.8) 1.25 mL - - 
10% SDS 100 µL 100 µL 100 µL 
10% APS 100 µL 100 µL 100 µL 
TEMED 10 µL 6 µL 4 µL 
 
Protein lysates were adjusted to a protein concentration of 30 µg and 4x Laemmli buffer was added. 
Samples were denatured for 5 min at 95°C and subsequently loaded on polyacrylamide gels next to a 
protein size marker. The gels were placed into a blotting chamber together with running buffer and 
electrophoresis was performed for 1.5-2 h at 85-150 V.  
For immunoblotting, a stack of Whatman filter papers, the separating gel and a nitrocellulose membrane 
were placed into a blotting chamber together with borate transfer buffer and blotting was performed for 
1.5 h at 90 V. Blotted membranes were blocked in 5% milk or BSA in TBST for 1 h and incubated with the 
respective primary antibodies (see Table 3.11) at 4°C on a shaker overnight. If not mentioned otherwise, 
β-actin served as loading control. The following day, membranes were washed 3x with TBST for 15 min 
and incubated with IRDye secondary antibodies (see Table 3.11) for 1 h at ambient temperature. After 
another washing step, fluorescence signals were detected using an Odyssey Sa Infrared Imaging System. 
4.3.3 Nuclear cytoplasmic fractionation 
NE-PER Nuclear and Cytoplasmic Extraction Reagents were used as described in the manufacturer’s 
instructions. An additional washing step was performed after isolation of the cytoplasmic fraction to 
increase purity of the nuclear fraction. Fractionated samples were immunoblotted as described above. 
PARP and β-tubulin served as loading controls for the nuclear and cytoplasmic fractions. 
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4.3.4 Co-immunoprecipitation 
Co-immunoprecipitation (CoIP) was used to study protein-protein interactions. Cells were seeded onto 
15 cm cell culture dishes and transfected with 1 µg of the KPNA2 (pDest-N-HA-KPNA2) and E2F1 or TFDP1 
(pDest-N-FLAG-E2F1 or pDest-N-FLAG-TFDP1) expression vectors using the Fugene HD Reagent the 
following day. CoIP assay was started 24 h after transfection.  
For each sample, 50 µL Dynabeads Protein G were incubated in Glycine (pH 2.8) for 5 min at ambient 
temperature followed by 4 h of incubation with 2 µg antibody/PBST (see table 3.11) at 4°C on an overhead 
rotator. IgG was used as a negative control. Plasmid-transfected cells were washed twice and scraped in a 
non-denaturing CoIP lysis buffer supplemented with DTT, PMSF and protease inhibitor. Lysates were 
incubated for 15 min while rotating at 4°C and centrifuged for 15 min (18,000 x g) to remove cell debris. 
The protein concentration was measured using Bradford reagent and adjusted to 1 mg/mL. 20 µL of every 
sample was removed as input control for immunoblotting. After antibody incubation, Dynabeads Protein 
G were washed twice using DPBS and 1 mL cell lysate was added. The Dynabeads/lysate mixture was 
incubated overnight at 4°C while rotating. The following day, the Dynabeads were washed three times 
using DPBS and resuspended in 1x Laemmli buffer. After 20 min of shaking (500 rpm) at ambient 
temperature samples were denatured for 8 min at 95°C and western blot was performed as described 
above. To avoid artefacts of the heavy chains of antibodies or IgG, the Quick Western Kit – IRDye® 680RD 
was used for antibody incubation according to the manufacturer’s instructions.  
4.3.5 Quantitative proteomics. 
To asses differential protein expression upon KPNA2 depletion, HLE cells were treated with a siRNA 
targeting KPNA2 (KPNA2#1) or the AllStars negative control. Liquid chromatography-tandem mass 
spectrometry was carried out at the European Molecular Biology Laboratory (EMBL, Heidelberg, Germany) 
in collaboration with the Beck group as previously described [61].  
In brief, cells were harvested using an urea and Rapigest containing lysis buffer followed by sonication, 
reduction of solubilized proteins by addition of DTT and alkylation of cystein using idoacetaminde. In a 
next step, proteins were digested using LysC and trypsin. TFA was added to acidify the samples before they 
were further cleaved by heat-induced Rapigest activation. Afterwards, samples were centrifuged and the 
supernatants were desalted using C18 spin columns. Peptides were analyzed using a nano-Acquity UPLC 
(Ultra performance liquid chromatography) system connected to a LTQ-Orbitrap Velos Pro instrument. 
Quantitative label-free data analysis was performed using MaxQuant v1.2.2.5. MS/MS spectra were 
matched with human SwissProt entries. Results were analyzed using R v2.14.2 by the Beck Laboratory. 
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4.4  Functional assays 
4.4.1 Colony formation assay 
Colony formation assays were performed to analyze clonogenic capacity in presence or absence of KPNA2 
and stathmin. Two days after siRNA-mediated knockdown of KPNA2 or stathmin, cells were re-seeded in 
a very low density (HLE: 500 cells/well; Snu182: 1000 cells/well) into a 6-well plate. 14 days after siRNA-
treatment colonies were stained for 35 min using a 1% crystal violet solution. The number of colonies was 
counted and evaluated compared to the All-Stars negative control. 
4.4.2 Migration assay 
Migration of HLE and Snu182 cells upon KPNA2 or stathmin depletion was analyzed using a “scratch” assay. 
Cells were seeded into 12-well-plates and treated with siRNAs targeting KPNA2 or stathmin. 48 h after 
protein knockdown, cells were treated with mitomycin C (5 µg/µL) in serum-free medium for 3 h to repress 
proliferation. After removal of mitomycin C, the cell monolayer was scratched using a 200 µL pipette tip 
and hepatocyte growth factor (HGF, 10 ng/mL) was added to enhance cell migration. Migration was 
monitored using an inverse microscope (Olympus CKX41) with connected camera by taking four pictures 
per scratch 0 h and 18 h after scratching. The cell free area was quantified using the software Fiji. 
4.4.3 Cell cycle assay 
To study the influence of KPNA2 on cell cycle kinetics, cells were treated with siRNAs targeting the 
respective gene in duplicates. Cells were fixed and cellular DNA was stained using the Guava® Cell Cycle 
Reagent 72 h after treatment according to the manufacturer’s protocol. The percentage of cells in the 
different cell cycle phases was analyzed using a Guava easyCyte flow cytometer (10,000 cells/sample). For 
data analysis, peaks were annotated to the respective cell cycle phase according to the measured DNA 
content.   
4.5  Analysis of murine and human HCC samples 
4.5.1 Tissue microarray 
The HCC tissue microarray (TMA) was kindly provided by the Tissue Bank of the National Center for Tumor 
Diseases (NCT) Heidelberg and approved by the local Ethics Committee. The TMA contained 95 formalin-
fixed paraffin-embedded human HCC samples with following tumor grades: 14x G1; 52x G2; 27x G3; 2x G4. 
Grading was conducted by an experienced pathologist. Immunohistochemical staining (i.e. H&E, KPNA2 
and stathmin staining) was carried out at the Institute of Pathology Greifswald (University Medicine 
Greifswald, Germany). For scoring, only tumor cells were assessed according to the scheme shown in 
Table 4.10. 
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Table 4.10: TMA scoring protocol. 
Score Quantity of stained cells Intensity of staining 
0 0% Negative (no staining) 
1 < 1% Low 
2 1-10% Moderate 
3 11-50% High 
4 > 50% - 
 
Staining of nucleus and cytoplasm were scored individually and independently by two researchers. The 
final IHC score was calculated by multiplication of quantity and intensity values per patient (dot on the 
array).  
4.5.2 Immunohistochemical staining of murine liver tissues 
Formalin-fixed paraffin embedded (FFPE) tissue samples originated from E2F1-driven murine HCCs (n=11; 
male; 9-15 months) were engineered and characterized by the Thorgeirsson Laboratory (Maryland, 
USA) [77] and kindly provided by Dr. Diego Calvisi. Immunohistochemical staining (i.e. H&E and stathmin 
staining) of full FFPE sections was carried out at the Institute of Pathology Greifswald (University Medicine 
Greifswald, Germany) and analyzed by an experienced pathologist.  
4.5.3 Expression and survival analysis of human HCCs 
To analyze expression of KPNA2, stathmin, E2F1 and TFDP1 in human HCC and adjacent tissue a published 
Affymetrix U133A2.0 gene expression data set (Gene Expression Omnibus accession number GSE14520) 
originating from 256 HCC patients (247 tumor and 239 adjacent non-neoplastic samples) was used. The 
majority of patients developed HCC on the background of HBV infections. All patients underwent total 
tumor resection. For 242 patients survival data existed [78]. Complementary, a second published HCC 
patient cohort, the TCGA LIHC cohort (the cancer genome atlas, liver hepatocellular carcinoma, accessible 
via: http://cancergenome.nih.gov) was analyzed. The TCGA LIHC cohort contains HCC samples of 371 
patients of mixed sex and etiologies and Caucasian and Asian background. 
4.6  Statistical analyses 
Data are presented as means ± standard deviation. Expression differences between two different test 
conditions were compared by non-parametric two-tailed Mann-Whitney U tests using SPSS Statistics24. 
For statistical analysis of correlations, the Spearman's rank correlation coefficient was calculated with SPSS 
Statistics24 or GraphPad Prism 6. Overall survival was assessed by Kaplan-Mayer analysis using GraphPad 
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Prism 6. p-values < 0.05 were considered significant with the following gradation: * p<0.05; ** p<0.01 and 
*** p<0.001.  
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5 RESULTS 
5.1 Members of the nuclear transport machinery are deregulated in HCC 
A deeper understanding of the molecular mechanisms shaping the malignant phenotype of HCC is 
crucial to identify novel drug targets and to enable development of new therapeutic approaches [43]. 
Substantial deregulation of members of the nuclear transport machinery was previously described in 
different cancers [48, 49, 51, 61, 79]. Winkler et al. analyzed a published DNA microarray dataset 
(GEO: GSE50579) of 40 human tumor and seven non-tumorous liver samples and thereby identified a 
subset of overall 37 nuclear transport-related genes to be differentially expressed in HCC [61, 80]. The 
most prominently overexpressed genes included exportin-1 and -2 (XPO1, also CRM1; and XPO2, also 
CAS) and the karyopherins-α1 and 2 (KPNA1 and KPNA2) [61]. The authors could further demonstrate 
prosurvival properties of the CAS/KPNA2 transport cycle in HCC, being repressed by p53 [61]. However, 
several functional and mechanistic aspects of KPNA2 in HCC remain to be defined. 
To follow up on the above-mentioned data and prior to further functional and mechanistic studies, the 
protein expression of KPNA2 was evaluated in different liver derived cancer cells lines and the 
immortalized hepatocyte cell line THLE-2.  
 
Figure 5.1: KPNA2 expression in liver cancer cell lines. Western blot analysis of KPNA2 expression in the 
immortalized hepatocyte cell line THLE-2 and different liver cancer cell lines. Samples were immunoblotted 
using the indicated antibodies.  
 
As depicted in Figure 5.1, THLE-2 cells showed the lowest KPNA2 expression compared all analyzed 
cancer cell lines, supporting the reported overexpression of KPNA2 in human HCC patient samples [61]. 
Based on the strong protein expression and their favorable cell culture behavior, HLE cells were chosen 
as standard cell line for further experiments.  
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5.2 Quantitative proteomics reveals regulation of microtubule-related proteins by 
KPNA2 
A proteomics approach was used to identify downstream targets of KPNA2 and to further elucidate its 
functional role in HCC. Therefore, KPNA2 was depleted in HLE cells by siRNA-treatment (siRNA 
KPNA2#1) and changes in total protein abundance were analyzed 72 h later by quantitative mass 
spectrometry (n=3; Figure 5.2 A). Using a label-free technique, where control and treatment conditions 
are measured individually, sample preparation included protein isolation, reduction, alkylation and 
finally digestion into peptides [81]. Subsequently, samples were separated by UPLC and analyzed using 
tandem mass spectrometry (LC-MS/MS), which allows collection of detailed information of the 
analyzed peptides compared to conventional LC-MS techniques [81, 82]. Peptides and proteins were 
then identified by database comparison (human SwissProt) and expression differences between the 
control siRNA and KPNA2 siRNA treated groups were quantified.  
1759 proteins were measured in total. Table 5.1 shows a subset of the most deregulated proteins upon 
KPNA2 knockdown relative to the control samples. The 35 most up- and downregulated hits are 
summarized in Supplementary tables S1 and S2. 
Table 5.1: Selected proteins differentially expressed upon KPNA2 depletion. HLE cells were treated with a 
siRNA directed against KPNA2 (KPNA2#1) or a control siRNA and changes in global protein abundance were 
analyzed by LC-MS/MS. TPX2: Targeting protein for Xenopus kinesin-like protein 2; GSTF1: Gametocyte-
specific factor 1; HMOX1: Heme oxygenase 1. 
Protein Fold change (log2) p-value 
KPNA2 -4.07 2.22*10-8 
TPX2 0.80 7.14*10-5 
Syntenin-1 -1.39 0.0002 
Vinculin -0.64 0.0005 
Stathmin -0.92 0.0034 
GTSF1 -1.47 0.0043 
HMOX1 0.44 0.0075 
 
As demonstrated by the volcano plot (Figure 5.2 B), data analysis revealed differential regulation of the 
MT-associated proteins stathmin (gene: STMN1) and targeting protein for Xenopus kinesin-like 
protein 2 (TPX2) following KPNA2 depletion. Total protein abundance of stathmin was reduced by 50% 
while other members of the stathmin family were not identified in the dataset. For TPX2 a 1.75-fold 
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increase in protein expression was found upon KPNA2 knockdown. Consistent with this finding, it was 
previously shown that TPX2 is inactivated by binding to KPNA2 and that sequestration of KPNA2 by the 
Golgi matrix protein GM130 is required for TPX2-mediated microtubule nucleation during mitosis [83]. 
Due to this already reported link to KPNA2, TPX2 was not subjected to further analysis. However, 
stathmin with its well documented oncogenic role in (liver-) cancer [65, 66, 72, 74, 84] and no found 
published link to KPNA2 stathmin was considered a promising candidate for further validation. 
 
Figure 5.2: Stathmin is downregulated following KPNA2 depletion. (A) Workflow of quantitative mass 
spectrometry: HLE cells were treated with a siRNA directed against KPNA2 or a control siRNA and cells were 
harvested and lysed 72 h later. Following protein digestion, samples were analyzed using a nano-Acquity 
UPLC system connected to a LTQ-Orbitrap Velos Pro instrument (LC-MS/MS, n=3). Quantitative label-free 
data analysis was performed using MaxQuant and MS/MS spectra were matched with human SwissProt 
entries. (B) HLE cells were treated as described in (A) and changes in global protein abundance were 
analyzed by LC-MS/MS. Volcano plot shows the resulting changes in global protein abundances (log2 fold 
changes) relative to the control and the corresponding p-values (log10). Horizontal dotted line: p=0.01; 
vertical dotted lines: log2 fold change +/-0.8.  
 
5.3 KPNA2 is required for full expression of STMN1 
Immunoblotting was used to validate the reduction of stathmin protein upon KPNA2 depletion as 
indicated by the proteomic approach. Indeed, also by including two additional siRNAs all tree KPNA2 
knockdown conditions caused a reduction in stathmin protein abundance as indicated by western blot 
analysis (Figure 5.3 A). Since siRNAs KPNA2#1 and KPNA2#2 showed similar effect sizes, these siRNAs 
were used in further experiments. Also, other factors suggested to be deregulated based on the 
proteomic data set were tested by immunoblotting: gametocyte-specific factors 1 (GSF1), home 
oxygenase 1 (HMOX1) and Syntenin-1. As depicted in Figure 5.3 B (left panel), downregulation of GSF1, 
a protein predominately expressed in male germ cells and involved in spermatogenesis, and 
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upregulation of HMOX1, which is reportedly associated in inflammatory processes within the liver [85–
87], could be validated with both siRNAs. Inconclusive results were obtained for Syntenin-1 (melanoma 
differentiation-associated gene 9, MDM9), a highly conserved protein related to cancer invasion in 
different tumor entities [88, 89], for which siRNAs KPNA2#1 and #2 showed opposing effects 
(Figure 5.3 B, right panel). 
The effect of KPNA2 depletion on stathmin protein was observed not only in HLE, but also in the HCC 
cell lines HLF and Snu182 (Figure 5.3 C). Snu182 cells, which also showed strong KPNA2 expression in 
the liver derived cancer cell line screening (figure 5.1), were chosen as second cell line for further 
studies to ensure cell line independence of the results. For further experiments in Snu182 cells, siRNAs 
KPNA2#1 and #2 were pooled. Interestingly, exogenous (over)expression of KPNA2 does not further 
increase stathmin protein abundance (Figure 5.3 D). This observation is possibly due to the already high 
KPNA2 expression reflecting a saturated system. Additionally, qRT-PCR analyses showed that reduced 
stathmin protein levels upon KPNA2 knockdown were paralleled by a significant decrease in mRNA 
expression levels (Figure 5.3 E), suggesting a transcriptional level of regulation.  
In conclusion, the above presented LC-MS/MS dataset revealed a connection between the nuclear 
import receptor KPNA2 and the MT-interacting protein stathmin which could be further validated by 
western blot. Reduced STMN1 mRNA levels following KPNA2 depletion suggest a regulation at the 
transcript level. In a next step, functional significance of KPNA2 related to stathmin was evaluated.  
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Figure 5.3: KPNA2 depletion induces downregulation of stathmin. HLE cells were treated with siRNAs 
targeting KPNA2 or a control siRNA (ctrl). Changes in protein abundance were analyzed 72 h later by 
immunoblotting using the indicated antibodies. (B) HLE cells were treated as described in (A) and changes 
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in protein abundance were analyzed 72 h later by immunoblotting using the indicated antibodies. (C) HLE, 
HLF and Snu182 cells were treated as described in (A). Changes in protein abundance were analyzed 72 h 
later by immunoblotting using the indicated antibodies. (D) PLC cells were either left untreated (untr.) or 
transfected with a control plasmid (pcDNA3) or a plasmid encoding KPNA2 (N-EGFP KPNA2) and protein 
expression was analyzed 24 h later by immunoblotting using the indicated antibodies. (E) HLE and Snu182 
cells were treated as described in (A) and STMN1 mRNA expression was analyzed by qRT-PCR (HLE: n=5, SD 
ctrl: +/- 0.007; **p<0.01; Snu182: n=4; SD ctrl: +/- 0.001; *p<0.05). qRT-PCR data were normalized to the 
respective control siRNA. 
(B)  
5.4 Functional properties of KPNA2 and stathmin in HCC 
5.4.1 KPNA2 and stathmin are required for full clonogenic capacity of HCC cells 
The function of stathmin in cell cycle and mitosis, as well as in tumor invasion and metastases is well 
reported [70, 71, 73]. Therefore, it was hypothesized that KPNA2 depletion and the associated decrease 
of stathmin expression leads to a reduction in clonogenic potential, cell cycle arrest and/or decreased 
migratory capacity of HCC cells. Prior to further experiments, two different stathmin siRNAs were 
tested in HLE cells and displayed substantial knockdown of stathmin as indicated by western blot 
analysis (Figure 5.4).  
 
Figure 5.4: Testing of stathmin siRNAs. HLE cells were treated with siRNAs targeting stathmin or a control 
siRNA (ctrl). Changes in protein abundance were analyzed 72 h later by immunoblotting using the indicated 
antibodies. 
 
To address the above-mentioned hypothesis, HLE and Snu182 cells were seeded in a very low density 
following siRNA-mediated KPNA2 depletion and colony formation was assayed 14 days after 
knockdown by crystal violet staining. In line with the proposed theory, significantly less colonies formed 
upon KPNA2 ablation compared to the control siRNA (Figure 5.5 A and B). Direct stathmin knockdown 
let to led to a similar or, in case of siRNA#1, more pronounced reduction of colony formation by 50-90% 
compared to the control condition, largely phenocopying the effect observed upon KPNA2 depletion 
(Figure 5.5 C and D). 
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Figure 5.5: Reduction of colony formation upon KPNA2 knockdown is phenocopied by stathmin depletion. 
(A) HLE cells were treated with siRNAs directed against KPNA2 or a control siRNA (ctrl) and colony formation 
was analyzed 14 days later by crystal violet staining (n=4; *p<0.05). (B) Snu182 cells were treated with an 
siRNA pool (KPNA2#1/2) directed against KPNA2 or a control siRNA (ctrl) and colony formation was analyzed 
14 days later by crystal violet staining (n=4; *p<0.05). (C) HLE cells were treated with siRNAs directed against 
stathmin or a control siRNA (ctrl) and colony formation was analyzed 14 days later by crystal violet staining 
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(n=4; *p<0.05). (D) Snu182 cells were treated with an siRNA pool (stathmin#1/2) directed against stathmin 
or a control siRNA (ctrl) and colony formation was analyzed 14 days later by crystal violet staining (n=4; 
*p<0.05). All quantifications are shown relative to the respective control condition. 
 
5.4.2 KPNA2 is potentially involved in cell cycle progression 
Cell cycle dependent regulation of stathmin was extensively reported [90, 91]. It is well documented 
that stathmin is inactivated by phosphorylation at four serine residues as a cell enters mitosis and that 
stathmin depletion causes cell cycle arrest in the G2/M phase of mitosis [90, 92–94]. For the 
involvement of KPNA2 in cell cycle control and progression, controversial results were reported so far. 
Huang et al. found evidence that KPNA2 depletion leads to G1 phase arrest via modulation of Akt and 
FOXO3a phosphorylation in epithelial ovarian carcinoma [95]. In contrast, two studies carried out in  
NSCLC and esophageal squamous cell carcinoma cell lines showed that KPNA2 knockdown results in 
G2/M phase arrest [49, 96]. Therefore, the role of KPNA2 in cell cycle in HCC was studied by siRNA-
mediated KPNA2 depletion in HLE cells. Subsequently, the distribution of cells to G1, S and G2 phase 
was assessed according to the DNA copy number of single cells using propidium iodide staining in 
combination with flow cytometry. Preliminary results indicate a reduced percentage of HLE cells in G2 
phase by roughly 10% following KPNA2 knockdown (Figure 5.6). Noteworthy, a larger fraction off cells 
did not appear to distributed to G1, S or G2 phase following KPNA2 depletion than in the control 
conditions. Limiting the explanatory power of cell cycle analysis, this technique does not allow to 
distinguish between viable and apoptotic cells. However, to draw firm conclusions about the function 
of KPNA2 in cell cycle progression in HCC cells further analysis is required. 
 
Figure 5.6: KPNA2 expression is involved in cell cycle progression. HLE cells were treated with siRNAs 
targeting KPNA2 or a control siRNA (ctrl) and distribution of cells to different cell cycle phases was analyzed 
48 h later using flow cytometry (n=1). 
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5.4.3 KPNA2 and stathmin are required for full migratory capacity of HCC cells 
To assess the involvement of the KPNA2-stathmin-axis in migration in HCC, two-dimensional scratch 
assays following KPNA2 and stathmin knockdown were performed. HLE cells were plated in high density 
and 48 h after siRNA treatment tumor cell proliferation was suppressed by Mitomycin C and migration 
stimulated by hepatocyte growth factor (HGF) treatment. As shown in Figure 5.7 A, HLE cells showed a 
significant reduction in migration following KPNA2 depletion compared to the control condition 18 h 
after the scratch was performed. An even more pronounced effect was observed upon stathmin 
knockdown indicated by an up to 70% reduction in gap closure compared to the control treatment 
(Figure 5.7 B).  
 
Figure 5.7: Reduction of migration capacity upon KPNA2 knockdown is phenocopied by stathmin 
depletion. (A) HLE cells were treated with siRNAs directed against KPNA2 or a control siRNA (ctrl) and two-
dimensional scratch assay was performed 48 h later. Cell free areas were analyzed 0 h and 18 h after 
scratching (n=4; *p<0.05).  (B) HLE cells were treated siRNAs directed against stathmin or a control siRNA 
(ctrl) and two-dimensional scratch assay was performed 48 h later. Cell free areas were analyzed 0 h and 
18 h after scratching (n=4; *p<0.05). All quantifications are shown relative to the respective control 
condition. 
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These data suggest that KPNA2 is required for the full clonogenic and migratory capacity of HCC cells 
by maintaining stathmin expression. Thus, the mechanism by which KPNA2 regulates stathmin 
expression was assessed as a next step of this study. 
5.5 KPNA2 regulates STMN1 expression by nuclear import of its transcription factors 
E2F1 and TFDP1 
5.5.1 KPNA2 depletion does not modulate phosphorylation of stathmin 
It was first tested whether KPNA2 modulates stathmin phosphorylation as a critical determinant in 
stathmin activity. Phosphorylation of stathmin was previously observed not only during mitosis but also 
in response to activation of different intracellular signaling pathways (e.g. MAPK, CDK, PKA and STAT3 
signaling) [66, 97]. Besides inactivation, phosphorylation was also reported to cause partially protein 
degradation [98]. To exclude phosphorylation and subsequent inactivation/degradation of stathmin by 
KPNA2 knockdown western blot analysis of stathmin phosphorylation (P-stathmin S38) was performed. 
As shown in Figure 5.8, phosphorylation status of stathmin did not change following KPNA2 depletion 
in HLE cells.   
 
Figure 5.8: KPNA2 knockdown does not modulate stathmin phosphorylation. HLE cells were treated with 
siRNAs directed against KPNA2 or a control siRNA (ctrl) and stathmin phosphorylation was analyzed 72 h 
later by immunoblotting using the indicated antibodies. 
 
5.5.2 Screening for STMN1 transcription factors 
Since no evidence for an association between KPNA2 depletion and stathmin phosphorylation was 
found and STMN1 transcript levels were decreased upon KPNA2 knockdown it was hypothesized that 
KPNA2 regulates stathmin by import of its transcription factors. By evaluation of the STMN1 promoter 
region and its binding sites using online databases (PROMO3.0, accessible via 
http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3; TFBIND, accessible via 
http://tfbind.hgc.jp/) numerous possible transcription factors were identified (e.g. FoxM1, members of 
the MAPK family). Based on the initial hits, literature research was performed to narrow down the 
number of possible transcription factors to the most promising candidates (Table 5.2). 
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Table 5.2: STMN1 transcription factor candidates. Online database and literature research were combined 
to identify the most promising candidates that could act as STMN1 transcription factors. FBP-1/2: fuse 
binding protein 1/2. 
Candidate Entity Reference 
FBP-1/2 NSCLC [73, 99] 
c-JUN Rat-1a (rat fibroblasts) [100] 
E2F1 HCC [101] 
TFDP1 HCC [101, 102] 
 
Subsequently, nuclear and cytoplasmic fractionation assays and CoIP were used to analyze the nuclear 
import of and direct binding to the above-mentioned transcription factors by KPNA2. Direct protein 
knockdown of the candidates was performed to assay the downregulation of STMN1 following 
depletion of the predicted transcription factors. 
5.5.3 FBP-1/2 and c-JUN are not involved in KPNA2-mediated STMN1 regulation 
According to the hypothesis that KPNA2 acts as nuclear import receptor for STMN1 transcription 
factors, depletion of KPNA2 would result in retention of the respective candidate protein in the 
cytoplasm. Therefore, HLE cells were treated with siRNAs directed against KPNA2 or a control siRNA 
and the nuclear-cytoplasmic distribution of FBP-1, FBP-2 and c-JUN was analyzed 72 h later using 
nuclear and cytoplasmic fractionation assay. As depicted in Figure 5.9 A, FBP-1 and FBP-2 showed no 
difference in their subcellular distribution following KPNA2 depletion while c-JUN protein abundance 
was increased in the cytoplasmic and decreased in the nuclear fraction as detected by immunoblotting. 
To further confirm the direct physical interaction of KPNA2 and c-JUN, CoIP was performed. Thus, 
KPNA2 was immunoprecipitated and co-binding of c-JUN was assessed using western blot. In line with 
the hypothesis and the findings of the fractionation assay, the direct interaction of KPNA2 and c-JUN 
was confirmed in HLE and Snu182 cells (Figure 5.9 B). 
Acting as STMN1 transcription factors, direct depletion of the candidates should result in decrease in 
STMN1 transcription and subsequently in STMN1 mRNA levels. Thus, HLE cells were treated with siRNAs 
targeting FBP-1, FBP-2 and c-JUN and STMN1 expression was analyzed 72 h later using qRT-PCR. Data 
showed that FBP-1 strongly regulates STMN1 as its depletion leads to a striking downregulation of 
mRNA expression (Figure 5.9 C). On the contrary, knockdown of FBP-2 and c-JUN caused a moderate 
or no reduction in STMN1 mRNA levels (Figures 5.9 D and E).  
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Figure 5.9: Interaction of FBP-1, FBP-2 and c-JUN with KPNA2 and their regulation of STMN1 expression. 
(A) HLE cells were treated with siRNAs directed against KPNA2 or a control siRNA (ctrl) and nuclear and 
cytoplasmic fractionation assay was performed 72 h later. Samples were immunoblotted using the indicated 
antibodies. β-tubulin (cytoplasmic fraction) and PARP (nuclear fraction) served as loading controls. (B) 
Endogenous KPNA2 was immunoprecipitated in HLE and Snu182 cells and binding of KPNA2 and c-JUN was 
analyzed by immunoblot. IgG served as an IP control. (C, D, E) HLE cells were treated with siRNAs directed 
against FBP-1, FBP-2 or c-JUN or a control siRNA (ctrl) and STMN1 expression was analyzed 72 h later using 
qRT-PCR (n=2; FBP-1 knockdown: SD ctrl: +/- 0.007; FBP-2 knockdown: SD ctrl: +/- < 0.001; c-JUN 
knockdown: SD ctrl: +/- < 0.001). qRT-PCR data were normalized to the respective control siRNA.  
 
Consequently, FBP-1, FBP-2 and c-JUN were excluded as relevant players involved in KPNA2 dependent 
regulation of STMN1 transcription. c-JUN seemed to be a promising candidate due to its strong 
interaction with KPNA2, however, its depletion did not lead to a reduction in STMN1 mRNA expression. 
FBP-1 and FBP-2 could not be identified as transport substrates of KPNA2 in HCC cells. Therefore, other 
candidates were tested as follows. 
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5.5.4 KPNA2 facilitates the import of the STMN1 transcription factors E2F1 and TFDP1 
Consistent with the approach used for the above-mentioned candidates, it was tested whether E2F1 
and TFDP1 are KPNA2 nuclear import substrates and if they are STMN1 transcription factors. Thus, HLE 
cells were treated with siRNAs directed against KPNA2 and nuclear-cytoplasmic fractionation assay was 
performed 72 h later.  
 
Figure 5.10: KPNA2 mediates the nuclear import of E2F1 and TFDP1.  (A) HLE cells were treated with siRNAs 
directed against KPNA2 or a control siRNA (ctrl) and nuclear and cytoplasmic fractionation assay was 
performed 72 h later. Samples were immunoblotted using the indicated antibodies. β-tubulin (cytoplasmic 
fraction) and PARP (nuclear fraction) served as loading controls. (B) KPNA2 (N-HA KPNA2) was 
overexpressed in HLE and Snu182 cells in combination with E2F1 (N-Flag E2F1) and KPNA2 was 
immunoprecipitated 24 h later. Binding of KPNA2 and E2F1 was analyzed by immunoblot. IgG served as an 
IP control. (C) KPNA2 (N-HA KPNA2) was overexpressed in HLE and Snu182 cells in combination with TFDP1 
(N-Flag TFDP1) and KPNA2 was immunoprecipitated 24 h later. Binding of KPNA2 and TFDP1 was analyzed 
by immunoblot. IgG served as an IP control. 
 
As depicted in Figure 5.10 A, immunoblot analysis showed a retention of E2F1 and TFDP1 in the 
cytoplasmic fraction and subsequently a decrease in the nuclear fraction. The transcription factor ATF-2 
served as a negative control to exclude a general import defect. As a next step, CoIP was performed to 
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confirm direct interaction between KPNA2 and E2F1/TFDP1. Therefore, KPNA2 (N-HA KPNA2) was 
overexpressed in combination with E2F1 (N-Flag E2F1) or TFDP1 (N-Flag TFDP1) in HLE and Snu182 cells 
and CoIP assays were carried out 24 h later. Following immunoprecipitation of KPNA2, E2F1 
(Figure 5.10 B) and TFDP1 (Figure 5.10 C) could be detected as KPNA2 binding partners by 
immunoblotting, confirming KPNA2 as nuclear import receptor for both proteins.  
 
Figure 5.11: E2F1 and TFDP1 are required for full expression of STMN1. (A) HLE and Snu182 cells were 
treated with siRNAs directed against E2F1 or a control siRNA (ctrl) and STMN1 expression was analyzed 48 h 
later using qRT-PCR (n=4; *p<0.05; HLE SD ctrl: +/- 0.001; Snu182 SD ctrl: +/- < 0.001) or 96 h later by western 
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blot using the indicated antibodies. (B) HLE and Snu182 cells were treated with a siRNAs directed against 
TFDP1 or a control siRNA (ctrl) and STMN1 expression was analyzed 48 h later using qRT-PCR (n=4; *p<0.05; 
HLE SD ctrl: +/- < 0.001; Snu182 SD ctrl: +/- 0.002) or 96 h later by western blot using the indicated 
antibodies. (C) HLE and Snu182 cells were treated with a combination of siRNAs directed against E2F1 and 
TFDP1 or a control siRNA (ctrl) and STMN1 expression was analyzed 48 h later using qRT-PCR (n=4; *p<0.05; 
HLE SD ctrl: +/- 0.002; Snu182 SD ctrl: +/- < 0.001) or 96 h later by western blot using the indicated 
antibodies. qRT-PCR data were normalized to the respective control siRNA. 
 
Subsequently, direct siRNA-mediated knockdown of E2F1 and TFDP1 was performed. In line with the 
hypothesis, results showed significantly reduced STMN1 expression on protein and mRNA level as 
demonstrated by immunoblot and qRT-PCR analysis in HLE and Snu182 cells (Figures 5.11 A and B). 
Interestingly, combined depletion of E2F1 and TFDP1 did not further increase the effect on STMN1 
transcript or protein abundance compared to the individual knockdowns (Figure 5.11 C). In conclusion, 
the obtained data indicate that KPNA2 regulates STMN1 by nuclear import of its transcription factors 
E2F1 and TFDP1. Most likely due to the fact that the two proteins bind to DNA as heterodimers [103], 
combined depletion of both transcription factors does not increase the effect size on the STMN1 
transcription.  
5.5.5 E2F1 binds to the promoter region of STMN1 
To ascertain direct binding of E2F1 to the promoter region of STMN1 ChIP assays were performed. In a 
first step binding sites for E2F1 within the regulatory region of STMN1 were searched for using a publicly 
available ChIP-Seq database (accessible via https://www.encodeproject.org/). Indeed, three ChIP-Seq 
datasets for E2F1 IP in the cell lines HeLa-S3, K562 and MCF-7 were found (see Appendix). Each dataset 
showed two peaks indicating strong protein-DNA binding within the STMN1 promoter region. The 
respective DNA sequences were aligned resulting in two roughly 250 bp long consensus sequences. 
Subsequently, primers were designed to amplify sequences within the predicted binding sites. The E2F1 
binding sites within the STMN1 promoter are depicted in Figure 5.12 A. The promoter region of CDC2 
served as a positive control due to its reported interaction with E2F1 [104]. Following E2F1 IP, a 5-20-
fold larger amount of DNA was precipitated at the predicted STMN1 promoter binding sites compared 
to the IgG control IP, while no significant amount of DNA was obtained of the negative control region 
(Figure 5.12 B). Therefore, the data indicated direct binding of E2F1 to the regulatory region of STMN1.  
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Figure 5.12: E2F1 binds to the promoter region of STMN1. (A) Scheme of the predicted E2F1 binding sites 
within the STMN1 promoter and the negative control region as predicted by encodeproject.org. (B) E2F1 
was immunoprecipitated in HLE cells, ChIP assay was performed and precipitated DNA of the predicted 
STMN1 bindings sites was quantified using qPCR. DNA enrichment was quantified relative to the IgG control 
IP. One representative experiment is shown (n=2). BS: binding site; TS: transcription start site. 
 
5.6 Regulation of KPNA2 expression in HCC  
5.6.1 E2F1 and TFDP1 are not involved in the regulation of KPNA2 in HCC 
As shown in Figure 5.10, KPNA2 facilitates the nuclear import of E2F1 and TFDP1 in HCC. In addition, it 
was reported that E2F1 and TFDP1 act as KPNA2 transcription factors and thereby drive its 
overexpression in cancer [105, 106]. These data suggest a positive feedback loop in which KPNA2 
translocates its own transcription factors to the nucleus. Therefore, E2F1 and TFDP1 were depleted in 
HLE cells and KPNA2 mRNA expression was analyzed 48 h later by qRT-PCR. As depicted in Figure 5.13 A, 
measurement of two biological replicates showed inconsistent results for the two used siRNAs. Data 
analysis following TFDP1 knockdown showed no decrease of KPNA2 mRNA levels (Figure 5.13 B). In 
summary, no convincing evidence was found for the regulation of KPNA2 by E2F1/TFDP1 in HCC cells.  
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Figure 5.13: Regulation of KPNA2 expression by E2F1 and TFDP1.  (A) HLE cells were treated with siRNAs 
directed against E2F1 or a control siRNA (ctrl) and KPNA2 mRNA expression was analyzed 48 h later by 
qRT-PCR (n=2; SD ctrl: +/- 0.019). (B) HLE cells were treated with siRNAs directed against TFDP1 or a control 
siRNA (ctrl) and KPNA2 mRNA expression was analyzed 48 h later by qRT-PCR (n=2; SD ctrl: +/- < 0.001). Data 
were normalized to the respective control siRNA. 
 
5.6.2 KPNA2 is a p53 repression target in liver cancer 
The significance of mutations in the TP53 locus and alterations of the p53 pathway in tumor 
development, maintenance and progression is indisputable [22, 107, 108]. Winkler et al. previously 
reported repression of KPNA2 by p53 [61]. Following up on these findings, Sk-Hep1 and HuH6 cells were 
treated with Nutlin-3a or DMSO as a control for 24 h and 48 h and protein and mRNA expression were 
analyzed using immunoblotting and qRT-PCR. Recapitulating the results of the above-mentioned study, 
repression of KPNA2 by p53 could be confirmed in Sk-Hep1 cells (Figure 5.14 A) and further validated 
in HuH6 cells (Figure 5.14 B). Since p53 is frequently mutated in HCC and p53 gain-of-function 
mutations were demonstrated to drive overexpression of different (onco-)genes in cancer it was 
hypothesized that mutant p53 is involved in the strong expression of KPNA2 in liver cancer cell lines 
[108–111]. Therefore, p53 was depleted in the HCC cell lines HLE and Snu182 which harbor different 
p53 aberrations (HLE: 249 RS; Snu182: 215: SI [112, 113]) . However, knockdown of mutant p53 
did not change KPNA2 protein abundance (Figure 5.14 C). In summary, a strong negative regulation of 
KPNA2 by wildtype p53 induction could be confirmed by western blot and qRT-PCR in liver cancer in 
vitro. 
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Figure 5.14: KPNA2 is a repression target of p53.  (A) Sk-Hep1 cells were treated with Nutlin-3a for 24 h and 
48 h or DMSO as a control (ctrl) and analyzed by immunoblotting using the indicated antibodies and by 
qRT-PCR (n=2; SD ctrl: +/- < 0.001). (B) HuH6 cells were treated as described in (A) and analyzed by 
immunoblotting using the indicated antibodies and by qRT-PCR (n=2; SD ctrl: +/- < 0.001). (C) HLE and 
Snu182 were treated with siRNAs targeting p53 or a control siRNA (ctrl) and KPNA2 expression was analyzed 
72 h later by immunoblotting using the indicated antibodies. Vinculin served as loading control. qRT-PCR 
data were normalized to the respective control siRNA. 
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5.7 The Kpna2-E2f1/Tfdp1-Stathmin axis in murine HCC models 
5.7.1 Stathmin is overexpressed in murine HCC models with different genetic alterations 
To overcome the limitations of in vitro experiments, different strategies exist for induction of HCC in 
mouse models. Murine liver cancer models combine overexpression of oncogenes with depletion of 
tumor suppressor genes that were demonstrated to be aberrantly expressed in human HCC [114]. To 
follow up on the regulation of KPNA2 by p53, a collection of murine HCC samples was analyzed where 
HCCs developed in Black 6 mice with a p19ARF and/or Trp53 deleted background in combination with 
transposon-based expression of mutated N-ras (N-rasG12V), c-myc (MycOE) and/or Akt-1 in murine livers 
following hydrodynamic tail-vein injection (samples kindly provided by Dr. Daniel Dauch) [115].  
 
Figure 5.15: Stathmin is overexpressed in murine liver tumors with different genetic alterations. 
(A) Western blot analysis of KPNA2 expression in three Black 6 liver and 10 HCC tissue samples of mice 
harboring p53 wildtype or p53-/- background. Transgenes (N-rasG12V and Myc) were delivered using 
hydrodynamic tail-vein injection. Vinculin served as loading control (wt: wildtype; NT: non-tumorous liver 
tissue). (B) Densitometric analysis of the antibody signal intensities of the western blot depicted in (A). 
(C) Analysis of Stmn1 mRNA expression in three Black 6 liver and 11 HCC tissue samples of different genetic 
background. Transgenes (N-rasG12V, Myc and Akt-1) were delivered using hydrodynamic tail-vein injection. 
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mRNA expression was normalized to five different reference genes using GENORM. Results were normalized 
to the mean of the three non-tumorous samples. 
 
As depicted in Figure 5.15 A, western blot analysis of Trp53 wildtype versus depleted samples revealed 
a moderate to strong expression of Kpna2 compared to non-tumorous tissue (NT) in roughly 50% of 
the tested murine HCCs. In line with the previously indicated negative regulation of KPNA2 by p53, 
higher Kpna2 protein levels were observed in tumor samples obtained from Trp53-/- mice 
(Figure 5.15 B). Analysis of Stmn1 mRNA in the same mouse model showed a 4- to 12-fold increased 
expression in 10 out of 11 tested murine HCCs (Figure 5.15 C). Based on the genetic alterations of the 
mice, a specific pattern driving the overexpression of STMN1 could not be identified. Next to the 
negative regulation of KPNA2 by p53, these data suggest an overexpression of Kpna2 and Stathmin in 
murine tumor compared to normal liver tissue. 
5.7.2 Stathmin is overexpressed in an E2f1-driven murine HCC model  
An E2f1-driven HCC mouse model was used to analyze E2F1-dependent Stathmin expression in a setting 
closer to the human in vivo situation. Therefore, Conner et al. generated transgenic mice which express 
E2f1 under the control of an albumin-promoter and therefore in a liver specific manner [77]. 
Additionally, the authors experimentally validated binding of E2f1 to Tfdp1 by CoIP, ensuring that the 
two proteins  can form heterodimers and subsequently act as potent transcriptional activators in this 
model [77]. To analyze Stathmin expression, full FFPE sections of murine livers containing 
non-tumorous tissue, precursor lesions and HCC were H&E stained and by using immunohistochemistry 
(IHC) with a Stathmin antibody. As shown in Figure 5.16 A, already the precursor lesions (right column) 
showed a high Stathmin immunoreactivity compared to the adjacent liver tissue that became even 
more striking in the full-blown tumors (left column). All tumors found per mouse were evaluated 
individually. As depicted in Figure 5.16 B, a positivity for Stathmin was detected in all tumors found in 
the 11 tested transgenic mice with predominantly moderate to high staining intensity.  
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Figure 5.16: Stathmin is overexpressed in E2f1-driven murine liver tumors.  (A) Representative H&E (upper 
row) and stathmin staining (lower row) of transgenic E2f1-driven murine liver tumors (left column) and 
precursor lesions (right column). Full FFPE sections; scale bars: 100 µM (left column), 1 mm (right column); 
dotted lines indicate tumor boarder. (B) The bar diagram shows Stathmin protein expression of liver tumors 
in the individual transgenic mice as percentage of total liver tumors per mouse showing mild, moderate or 
strong Stathmin immunoreactivity (n=11; IHC: immunohistochemistry).  
 
5.8 The KPNA2-E2F1/TFDP1-stathmin axis in human HCC cohorts 
5.8.1 KPNA2 and STMN1 expression are correlated in human HCC tissue 
To correlate the obtained data to the human in vivo situation, KPNA2 and stathmin expression was 
investigated in human HCCs by using immunohistochemical staining of a tissue microarray (TMA) 
containing 95 HCC FFPE samples. Supporting the previous findings, a strong and highly significant 
correlation (r=0.73; p<0.0001) between the IHC scores of KPNA2 and stathmin was found 
(Figure 5.17 A). Immunoreactivity was additionally evaluated according to the respective tumor grades 
of the HCCs. As depicted in Figure 5.17 B a significant positive correlation between protein abundance 
and tumor grading was identified (KPNA2: r=0.48; p<0.0001; stathmin: r=0.39; p<0.0001).   
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Figure 5.17: KPNA2 and stathmin expression are correlated in human HCC. (A) A tissue microarray (TMA) 
containing 95 human HCC FFPE samples was either H&E stained (upper row) or immunoassayed with KPNA2 
(middle row) or stathmin (lower row) antibodies (r=0.73; p<0.0001; scale bar: 100 µm). (B) The whisker plots 
illustrate IHC scores of KPNA2 (upper panel) and stathmin (lower panel) dependent on tumor 
dedifferentiation (G1: well differentiated, n=14; G2: moderately, n=52; G3-4: poorly differentiated, n=29). 
 
In vivo expression of KPNA2 and stathmin was further evaluated analyzing transcriptomic data from a 
larger cohort of 247 HCC patients (Roessler cohort) [78]. Samples within this cohort predominantly 
origin from patients with a HBV infections and Chinese ethnicity [78].  Analysis of KPNA2 and STMN1 
RNA levels in tumor and adjacent non-tumorous liver tissue showed a significant overexpression of 
both proteins in HCC (Figure 5.18 A). Besides overexpression in HCC tissue, the correlation between 
KPNA2 and stathmin expression demonstrated in TMA samples was recapitulated on mRNA level 
(r=0.61; p<0.0001; Figure 5.18 B). Based on the observed KPNA2/stathmin-dependent effects on the 
clonogenic and migratory capacity, it was assumed that high levels of both factors correlate with a more 
aggressive phenotype as indicated by poor patient outcome. Thus, Kaplan-Meier analyses using survival 
data of the Roessler cohort was performed. In line with the above-mentioned assumption, patients 
with high expression of KPNA2 and/or STMN1 (cut-off: median) in tumor samples showed a poorer 
overall outcome (Figure 5.18 C).  
To validate results obtained by evaluation of the Roessler cohort, transcriptomic expression data from 
a second independent cohort were analyzed. The TCGA LIHC cohort (the cancer genome atlas, liver 
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hepatocellular carcinoma, accessible via: http://cancergenome.nih.gov) contains HCC samples of 371 
patients of mixed sex and etiologies and Caucasian and Asian background. Paralleling previous findings, 
the TCGA LIHC cohort revealed significantly higher expression levels of KPNA2 and STMN1 RNA in HCC 
compared to non-tumorous samples (Figure 5.18 D). Furthermore, a significant positive correlation 
between the expression levels of both factors was confirmed (r=0.63; p<0.0001; Figure 5.18 E). Finally, 
Kaplan-Meier analyses confirmed poorer overall survival in patients showing high expression of both 
factors (cut-off: median; Figure 5.18 F). In summary, it was demonstrated that KPNA2 and stathmin are 
overexpressed and positively correlated in human HCCs as shown by analysis of a HCC TMA and two 
independent HCC cohorts. Furthermore, in line with the involvement of KPNA2 and stathmin in 
clonogenicity and migration in vitro, high expression of both genes/proteins was associated with poor 
patient outcome. 
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Figure 5.18: KPNA2 and STMN1 are overexpressed and related to poor survival in HCC patient samples. 
(A) Analysis of transcriptomic data of KPNA2 and STMN1 expression in human HCC and adjacent non-
tumorous liver tissue of the Roessler cohort. (B) Spearman correlation between KPNA2 and STMN1 RNA 
expression in human HCC samples of the Roessler cohort. (C) Overall survival (Kaplan-Meier analysis) of 
patients of the Roessler cohort displaying a low and high expression of KPNA2 and STMN1 (cut-off: median). 
(D) Analysis of transcriptomic data of KPNA2 and STMN1 expression in human HCC and adjacent non-
tumorous liver tissue of the TCGA LIHC cohort. (E) Spearman correlation between KPNA2 and STMN1 RNA 
expression in human HCC samples of the TCGA LIHC cohort. (F) Overall survival (Kaplan-Meier analysis) of 
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patients of the TCGA LIHC cohort displaying a low and high expression of KPNA2 and STMN1 (cut-off: 
median). 
 
5.8.2 E2F1 is overexpressed in human HCC tissue 
The expression of E2F1 and TFDP1 in human HCC was studied using data of the TCGA LIHC cohort 
described above. As depicted in Figure 5.19 A, analysis of E2F1 and TFDP1 RNA levels revealed a 
significant overexpression of E2F1 in tumor compared to non-tumor tissue. However, for TFDP1 no 
aberrant RNA expression was found within this cohort. Controversially, evaluation of the Roessler 
cohort showed no differential expression of E2F1 in tumor and adjacent tissue (data not shown). 
Nevertheless, Kaplan-Meier analyses of overall survival of HCC patients exhibiting high and low 
expression of E2F1 and TFDP1 (cut-off: median) showed a significantly poorer outcome for patients 
highly expressing both genes (Figure 5.19 B). Thus, despite no difference in TFDP1 RNA levels were 
found between tumor and non-tumor samples, heterogeneity within the tumor group allowed 
association of patients with higher TFDP1 levels with a more aggressive phenotype.  
 
Figure 5.19: E2F1 is overexpressed and related to poor survival in HCC patient samples. (A) Analysis of 
transcriptomic data of E2F1 and TFDP1 expression in human HCCs and adjacent non-tumorous liver tissue 
of the TCGA LIHC cohort. (B) Overall survival (Kaplan-Meier analysis) of patients of the TCGA LIHC cohort 
displaying a low and high expression of E2F1 and TFDP1 (cut-off: median). 
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Ultimately, to link the in vitro demonstrated regulation of STMN1 by E2F1 and TFDP1, expression levels 
of the two transcription factors and STMN1 were correlated using the transcriptomic data of the 
Roessler cohort. As shown in Figure 5.20, a positive correlation between E2F1 and STMN1 (r=0.400; 
p<0.0001) and TFDP1 and STMN1 (r=0.382; p<0.0001) was found. In summary, the data support the 
here demonstrated mechanism by which KPNA2 regulates oncogenic STMN1 expression via the import 
of E2F1 and TFDP1 in HCC. As shown by patient data of the Roessler and TCGA LIHC cohorts, even in 
human HCCs which harbor manifold and complex genetic alterations overexpression of KPNA2 could 
be linked to stathmin and its transcription factors E2F1 and TFDP1.   
 
Figure 5.20: Expression of STMN1 and its transcription factors E2F1 and TFDP1 are correlated in HCC 
patient samples. (A) Spearman correlation between E2F1 and STMN1 RNA expression in human HCC 
samples of the Roessler cohort (n=247). (B) Spearman correlation between TFDP1 and STMN1 RNA 
expression in human HCC samples of the Roessler cohort (n=247).
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6 DISCUSSION 
6.1 Protumorigenic expression of stathmin is mediated by KPNA2-dependent 
nuclear import of E2F1 and TFDP1 in liver cancer 
Owing to its substantial role in nucleo-cytoplasmic translocation of oncogenes and tumor suppressors, 
the nuclear transport machinery is of outstanding importance in tumorigenesis [46, 51, 116]. Following 
up on previous data showing the aberrant expression of karyopherins in liver cancer [61], the functional 
and mechanistic role of KPNA2 was further elucidated. Here, a novel link between KPNA2 and the MT-
associated protein stathmin was identified using a proteomic approach. It was demonstrated that 
KPNA2 expression correlates with clonogenic and migratory capacity of HCC cells suggesting a 
protumorigenic role in hepatocarcinogenesis. Furthermore, the decrease in clonogenicity and 
migration upon KPNA2 depletion was phenocopied upon stathmin knockdown. Elucidating the 
underlying mechanism by which KPNA2 regulates the expression of STMN1, the transcription factors 
E2F1 and TFDP1 were identified as nuclear import substrates of KPNA2 (Figure 6.1).  
 
Figure 6.1: KPNA2 drives protumorigenic STMN1 expression by nuclear import of E2F1 and TFDP1. KPNA2 
binds to NLS of E2F1/TFDP1 and form a trimeric complex with KPNB. Upon translocated to nucleus through 
the NPC, the complex dissociates and E2F1 and TFDP1 can act as STMN1 transcription factors. 
 
Correlating these in vitro findings with data from murine and human HCC tissues, overexpression of 
KPNA2 and stathmin and a strong correlation to each other could be verified in vivo. In conclusion, 
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though extensively more research is needed, targeting KPNA2 could represent a promising therapeutic 
approach in treatment of HCC.   
6.2 Differential expression of nuclear transport factors in cancer 
Mediating nuclear import of oncogenes and/or tumor suppressors, nuclear transport factors are pivotal 
for regulation of (aberrant) gene expression in cancer [48, 51, 75]. Transcription factors of small 
molecular weight (i.e. < 40 kDa) such as β-catenin and SMADs 2-4 can enter the nucleus independently, 
however, the import of bigger molecules (e.g. STAT 1-3, p65) relies on nuclear transport receptors [46–
48, 51]. In general, nuclear transport is regulated by modifications of the cargo protein 
(e.g. phosphorylation, methylation), the abundance of the transport receptors and the quantity of 
nuclear pores [46]. In cancer, deregulation of nuclear import can occur on different levels and mainly 
involves masking of the nuclear localization signal, aberrant upstream signaling or protein 
modifications [46]. Subsequent mislocalization of proteins can severely alter cellular processes and 
therefore drive tumorigenesis [46]. For instance, the normal function of the tumor suppressor p53 as 
transcription factor relies on its localization in the nucleus [24, 27]. It is well known that many, if not 
most, human tumors harbor mutations in the TP53 locus [22, 26, 27]. However, sequestration of wild-
type p53 in the cytoplasmic compartment can also cause functional inactivation and was shown in 
different tumor entities (e.g. colorectal and ovarian cancer) [117, 118].   
With few exceptions, almost all members of the karyopherin family, including KPNA2, have been shown 
to be aberrantly expressed in human cancers [51, 61, 75, 116]. Within this thesis, it was shown that 
KPNA2 is not only strongly expressed in different liver cancer cell lines (Figure 5.1), but also in murine 
and human HCCs (Figures 5.17 and 5.18). Overexpression of KPNA2 could be caused by transcriptional 
as well as post-transcriptional mechanisms. Since KPNA2 was reported to be repressed by p53, one 
possible event could be de-repression resulting from inactivating mutations of wildtype p53 [49, 61]. 
Furthermore, the KPNA2 gene is located in the 17q24.2 region in which gene amplifications have been 
previously described in HCC [119]. At the post-transcriptional level, it was shown that the KPNA2 mRNA 
is a target of miRNA26b, which is downregulated in HCC [120]. Moreover, since tumors are highly 
proliferative tissues, upregulation of KPNA2 could be advantageous for cancer cells to mediate 
transcriptional activation of genes involved in (unlimited) cell growth.   
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6.3 Quantitative proteomics reveals regulation of stathmin by KPNA2 
Using quantitative proteomics, the MT-interacting protein stathmin was identified as “downstream 
target” of KPNA2 (Figure 5.2). Stathmin is an ubiquitously expressed cytosolic phosphoprotein which is 
essential for and tightly regulated during cell cycle and cell division based on its inhibitory effect on 
microtubules formation [70, 121]. Additionally, stathmin was previously reported to be involved in 
tumor development and progression [65, 72, 73, 84]. Since interaction of karyopherins and microtubule 
regulation was not described before, connecting KPNA2 and stathmin expression provides a novel link 
between nuclear import and the microtubule network. Interestingly, the proteomic dataset also 
indicated upregulation of TPX2 following KPNA2 depletion. TPX2 is a microtubule-associated protein 
involved in microtubule nucleation and spindle pole formation during mitosis and meiosis [122]. In line 
with the here presented data, it was previously shown that karyopherin alpha inhibits microtubule 
nucleation during M phase of mitosis by inactivation of TPX2 [123]. Besides other malignancies, TPX2 
was reported to be overexpressed in human HCC patient samples and associated with poor overall 
survival [124]. Moreover, TPX2 knockdown was linked to reduced tumor cell migration and invasion in 
vitro in HCC [123, 124]. Thus, stathmin and TPX2 could act as player and counter player in the regulation 
of microtubule dynamics with TPX2 compensating for the functional deficits upon KPNA2 depletion.  
Next to stathmin, the proteomic dataset proposed aberrant expression of different proteins following 
KPNA2 knockdown (Table 5.1). The strongest downregulation was found for serine and arginine rich 
splicing factor 6 (SRSF6) and GTSF1. SRSF6 is a splicing factor documented to be frequently amplified 
and overexpressed in colon and lung cancer [125]. Thus, deregulated expression of SRSF6 was shown 
to result in alternative splicing of oncogenes and tumor suppressor, thereby enhancing tumor 
formation [125]. GTSF1 is a protein mainly expressed in male germ cells and involved in 
spermatogenesis [85]. Downregulation of GTSF1 following KPNA2 depletion as recognized in the 
proteomics dataset was verified using a second siRNA by immunoblotting (Figure 5.3), suggesting 
KPNA2 as nuclear import receptor for GTSF1. Additionally, GTSF1 was recently shown to be 
overexpressed and related to clonogenicity and tumor size in liver cancer [85, 86]. Although validation 
of the decrease of protein abundance of Syntenin-1 following KPNA2 knockdown as shown by LC-
MS/MS analysis led to controversial results (Figure 5.3), other studies could demonstrate the 
significance of Syntenin-1 in cancer [89, 126, 127]. Syntenin-1 is a tandem PDZ domain containing 
protein involved in multiple cell signaling events located at the plasma membrane (e.g. receptor 
trafficking, cell adhesion, immunoregulation) [89, 126, 128]. In a liver cancer context, Liu et al. reported 
overexpression of Syntenin-1 in hepatoma cell lines compared to immortalized hepatocytes 
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(i.e. THLE-3) and were able to correlate the high Syntenin-1 expression to enhanced clonogenic and 
proliferative properties in vitro [127].   
Taken together, evaluation of the here presented LC-MS/MS dataset revealed differential regulation of 
multiple proteins involved in cancer biology. The connection of KPNA2 to factors involved in 
development, alternative splicing of tumor suppressors/oncogenes and regulation of the immune 
response underlines the central role of KPNA2 in nuclear import of proteins that mediate the malignant 
behavior of tumor cells. Focusing on the microtubule network, the proteomic data in combination with 
published studies point towards a complex functional and mechanistic involvement of KPNA2 in the 
regulation of microtubule associated proteins. Since stathmin and TPX2 are of fundamental significance 
for mitosis, their differential regulation in HCC is most likely required to maintain a highly proliferative 
phenotype.   
6.4 KPNA2 and stathmin expression drive colony formation and tumor cell migration 
in HCC  
The ability of cancer cells to sustain unlimited proliferation and to invade and metastasize are 
indisputable hallmarks of cancer [16]. Therefore, single tumor cells are capable of forming new colonies 
based on their unlimited proliferation capacity, which is also pivotal for invasion of surrounding tissues 
[16, 129]. In the here presented study it was demonstrated that the liver cancer cells show a significant 
reduction in clonogenic capacity following siRNA-mediated KPNA2 and stathmin depletion (Figure 5.5). 
In line with these findings, Noetzel et al. previously reported that the breast cancer cell line MCF-7 has 
a higher colony formation capacity than benign cells and that KPNA2 knockdown reduces the 
clonogenic potential of MCF-7 cells [130]. Similar results were found for shRNA-mediated KPNA2 
knockdown in the liver cancer cell lines HepG2 and SMMC-7721 [131]. Additionally, impaired 
clonogenic capacity was also described after stathmin depletion in esophageal and oral squamous cell 
carcinoma, lung adenocarcinoma and pancreatic cancer [132–135].  
Deregulation of migration pathways enables tumor cell migration and formation of metastases [136]. 
Thus, the significance of KPNA2 and stathmin expression for cancer progression in HCC was further 
underlined by the finding that depletion of both proteins results in a significant decrease in cell 
migration in HLE cells as indicated by two-dimensional scratch assays (Figure 5.7). Noteworthy, 
migration assay could not be performed in Snu182 cells due to high toxic effects following treatment. 
In order to inhibit proliferation and to secure measurement of migratory behavior itself cells were 
treated with Mitomycin C before scratching the cell monolayer [137]. Since a markedly higher cell 
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division rate was observed for Snu182 cells the loss in viability is most probably due to the higher 
sensitivity to Mitomycin C treatment. Paralleling the here shown data in HLE cells, it was previously 
demonstrated that KPNA2 knockdown decreases tumor cell migration in breast carcinoma and NSCLC 
cell lines [130, 138]. Consistent results were described after stathmin silencing in different entities 
including oral squamous cell carcinoma, NSCLC and most importantly in HCC [65, 73, 135]. As pivotal 
components of the cytoskeleton, microtubules and their regulatory proteins such as stathmin are 
crucial for cell migration and the therefore necessary re-orientation of the microtubules network [139]. 
Since stathmin has to be inactivate for mitosis, the fact that depletion of stathmin results in reduction 
of clonogenicity seems rather counter-intuitive. However, though extensively studied, not all 
mechanisms involved in cell cycle regulation are elucidated yet. Loss of stathmin could disbalance the 
complex signaling that tightly regulates mitosis. Since the functional decrease in colony formation and 
migration capacity following stathmin depletion exceeds the effect upon KPNA2 knockdown, the 
phenotype demonstrated after depletion of the latter could be due to the associated reduction in 
stathmin expression.  
6.5 KPNA2 regulates STMN1 by import of its transcription factors E2F1 and TFDP1 
6.5.1 KPNA2 facilitates the nuclear import of E2F1 and TFDP1 
Since KPNA2 is not known to act as transcription factor itself, regulation of stathmin expression was 
expected to rely on an indirect mechanism. Therefore, it was hypothesized that KPNA2 regulates 
stathmin by nuclear import of its transcription factors. It was previously demonstrated that siRNA 
mediated FBP-1 knockdown causes a decrease in stathmin expression in HCC and NSCLC [73, 99]. The 
FBP family member FBP-2 was assessed due to its reported co-regulation with stathmin, even though 
a transcriptional regulation could not be detected in the respective study [99]. However, respective cell 
fractionation experiments showed no accumulation of FBP-1 or -2 in the cytoplasm following KPNA2 
depletion (Figure 5.9), indicating that KPNA2 does not act as nuclear import receptor for FBP-1/-2. Thus, 
FBP-1/-2 were not considered relevant for KPNA2-dependent stathmin regulation although direct 
knockdown of FBP-1 caused a strong downregulation of stathmin expression on transcript level. Since 
FBP-1 contains a NLS [140], it is most likely imported into the nucleus by another member of the 
karyopherin family. Using a proteomic approach, Fukumoto et al. identified KPNA1 as nuclear import 
receptor of FBP-1 in murine brain tissue [141]. Additionally, another proteomic study in murine 
embryotic fibroblasts indicates nuclear import of FBP-1 by KPNA6 [142]. Assessment of the AP-1 
transcription factor c-JUN was conducted based on its regulation of stathmin in non-adherent Rat-1a 
cells (i.e. rat fibroblasts) as described by Kinoshita et al. [100]. Cell fractionation and CoIP experiments 
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confirmed nuclear import of c-JUN by KPNA2 (Figure 5.9). Controversially, Waldmann et al. reported 
that the nuclear import of c-JUN solely relies on karyopherin-beta and that the presence of 
karyopherin-alpha inhibits c-JUN translocation into the nucleus in HeLa cells [143]. In contrast, analysis 
of the control samples of the here shown fractionation experiment depicted the presence of c-JUN in 
the nucleus in the presence of KPNA2. However, subsequently direct knockdown of c-JUN showed no 
effect on stathmin expression levels. Thus, the here shown experiments indicate a nuclear import of c-
JUN mediated by KPNA2 but no transcriptional regulation of stathmin by c-JUN.  
Continuing the screening for stathmin transcription factors, nuclear import of E2F1 and TFDP1 by 
KPNA2 was analyzed. The E2F family comprises of several proteins that act either as transcriptional 
activators (E2F1-E2F3a) or repressors (E2F3b-E2F7) of genes involved in cell-cycle control  [103, 104]. 
In order to exert its role as transcription factor and to bind to DNA, E2F1 has to heterodimerize with 
the dimerization partner family member TFDP1, thereby allowing cooperative binding to and activation 
of the respective promoter regions of target genes [144]. It was previously reported that exogenous 
overexpression of E2F1 alone or in combination with TFDP1, but not of TFDP1 alone, enhances STMN1 
expression on mRNA level in the liver cancer cell lines HuH7 and Hep3B [101]. The here performed cell 
fractionation and CoIP experiments revealed a sequestration of E2F1 and TFDP1 in the cytoplasm 
following KPNA2 depletion and direct binding of both transcription factors to KPNA2 (Figure 5.10), 
indicating a nuclear import of both proteins by KPNA2. Consistent with these results, co-localization 
and direct binding of KPNA2 and E2F1 was previously found in NSCLC cells [49]. Moreover, Mackmull 
et al. recently published an interactome dataset of nuclear transport receptors and their cargo proteins 
generated by coupling a proximity ligation approach with mass spectrometry analysis (BioID technique) 
[102]. Thereby the authors identified TFDP1 and the E2F family members E2F3 and E2F6 as KPNA2 
transport cargo [102]. In contrast to the here presented data, E2F1 did not appear as KPNA2 interaction 
partner in this dataset which is mostly likely due to the use of HEK293 cells and their embryonic origin 
in the experimental setup, highlighting the importance of (liver) cancer specific interactome studies.   
6.5.2 E2F1 and TFDP1 transcriptionally regulate STMN1 expression 
Transient silencing of E2F1 and TFDP1 showed a decrease in STMN1 mRNA abundance following 
individual gene knockdown of roughly 40% which corresponds to the effect size observed upon KPNA2 
depletion (Figure 5.11). Interestingly, combined knockdown of E2F1 and TFDP1 did not further enhance 
the observed effect. Since E2F1 and TFDP1 cooperate to induce target gene expression as heterodimer 
[104], it is most likely that absence of one dimerization partner is sufficient to cause reduced 
transcriptional activation. Surprisingly, interrogating the proteomics data obtained after KPNA2 
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knockdown in HLE cells no other known E2F1 targets (e.g. CDK1 MCM2-7, MYC) showed up in this 
dataset [145]. This result is probably due to the indirect regulation via nuclear import and the possible 
use of alternative import receptors of the karyopherin family. Additionally, using different large-scale 
techniques (e.g. microarrays, ChIP-Seq) hundreds of E2F1 target genes have been proposed [145], 
however, systematic overview of E2F1-responsive genes is hard to achieve. Since transcription of 
STMN1 is only partially reduced following E2F1 and TFDP1 depletion the involvement of additional 
transcription factors is likely. As demonstrated in this thesis, FBP-1 is a potent STMN1 transcription 
factor that is not imported into the nucleus by KPNA2. Therefore, despite the absence of E2F1/TFDP1 
transcriptional activation of STMN1 can still be exerted by binding of FBP-1 to its promoter region. 
Interestingly, Malz et al. reported that the FBP-interacting repressor (FIR), which is overexpressed in 
HCC cell lines and patient samples, triggers tumor cell proliferation and migration via E2F1 and TFDP1 
dependent transcription of FBP-1 [146]. However, reduced abundance of FBP-1 was not detected 
analyzing the proteomic data generated following KPNA2 knockdown.  
In order to verify direct binding of E2F1 to the STMN1 promoter ChIP assays were performed. Analysis 
of three independent ChIP-Seq datasets upon E2F1 immunoprecipitation revealed two “binding 
hotspots” for E2F1 within the regulatory region of STMN1. Confirming the STMN1 binding sites, ChIP 
assays revealed strong binding of E2F1 to both predicted binding sites (Figure 5.12). In line with the 
here presented data, Chen et al. previously reported that combined exogenous overexpression of E2F1 
and TFDP1 enhances STMN1 promoter activity in the HCC cell lines HuH7 and Hep3B [101].  However, 
the authors could not demonstrate the independent importance of TFDP1 in STMN1 transcription. E2F1 
and TFDP1 cooperatively bind to DNA as heterodimer [144], therefore they have to be able to bind to 
the same DNA sequence. Despite this fact, additional alignment of ChIP-Seq datasets generated upon 
E2F1 and TFDP1 pulldown showed the highest scores for protein-DNA binding in close proximity, but 
distinct regions of the STMN1 promoter (data not shown). Thus, high affinity of one dimerization 
partner might be sufficient to enable promoter binding. To address this theory, additional ChIP 
experiments could be performed to analyze binding of E2F1 and TFDP1 to the STMN1 promoter 
prediction site of the respective other dimerization partner.  
6.6 Regulation of KPNA2 expression 
Additional to the nuclear import of E2F1 and TFDP1 by KPNA2 it was previously reported that E2F1 acts 
as KPNA2 transcription factor[105, 106], suggesting a possible positive feedback loop. However, the 
here performed experiments indicated no convincing transcriptional regulation of KPNA2 by E2F1 or 
TFDP1 in HCC cells (Figure 5.13). Despite confirmed binding of E2F1 and TFDP1 to the KPNA2 promoter 
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in lung and cervical cancer cells, van der Watt et al. did only demonstrate an effect of TFDP1, but not 
of E2F1 on KPNA2 protein expression in the above mentioned publication [105]. Noteworthy, Wang et 
al. showed KPNA2 downregulation on protein and mRNA level following combined depletion of E2F1 
and TFDP1 in NSCLC without distinguishing between the regulatory impact of the single transcription 
factors [106]. Taken together, there is strong evidence for E2F1 and TFDP1 binding sites within the 
KPNA2 promoter region, however, so far both cited publications lack individual knockdown of E2F1 and 
TFDP1 as well as appropriate control by the use of two individual siRNAs. Therefore, the transcriptional 
activation of KPNA2 by E2F1 and TFDP1 remains to be further elucidated.  
In normal cells p53 is usually inactivated by binding to its inhibitor MDM2 and located in the cytoplasm 
and translocates only into the nucleus upon cellular stress [147]. It was previously reported that p53 
harbors three NLS which allow binding to members of the karyopherin-alpha family and that vice versa 
p53 inhibits KPNA2 expression [61, 148, 149]. Following up on the by Winkler et al. reported repression 
of KPNA2 by p53 in liver cancer [61], this finding could be confirmed in the here presented study 
(Figure 5.14). However, mRNA expression of KPNA2 was affected to a lesser extent than protein 
abundance by p53 induction, suggesting the additional involvement of posttranslational regulation. 
Mutations of p53 not only cause functional inactivation of the resulting protein, they were also 
demonstrated to promote protumorigenic processes [108, 110]. Since the cell lines used in this study 
harbor mutations within the TP53 locus, it was hypothesized that expression of mutated p53 could 
drive overexpression of KPNA2 in liver cancer. However, in line with previous findings [61], knockdown 
of mutated p53 (HLE: 249 RS; Snu182: 215: SI [112, 113]) did not cause the expected reduction in 
KPNA2 protein abundance. Therefore, overexpression of KPNA2 in HCC is most likely driven by 
inactivation of wildtype p53 signaling (e.g. by mutational and/or functional inactivation, cytoplasmic 
sequestration) in HCC. Furthermore, it has to be evaluated if other p53 mutations and especially gain-
of-function mutations enhance KPNA2 expression. Therefore, further experiments are needed to study 
the impact of mutation, localization and functionality of p53 in a karyopherin-dependent context.     
6.7 In vivo significance of the KPNA2-E2F1/TFDP1-stathmin axis 
6.7.1 Kpna2 and Stathmin in murine HCC models 
Samples of two different mouse models were used to evaluate the biological significance of Kpna2, 
E2f1/Tfdp1 and Stathmin in vivo. Analysis of HCC tissue samples of different genetic origin generated 
by Dauch et al. [115] revealed overexpression of Kpna2 on protein and of Stmn1 on mRNA level in 
murine HCCs compared to non-tumorous liver tissue (Figure 5.15). Methodologically, comparison 
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between Kpna2 protein and Stmn1 mRNA expression was chosen as suitable approach since data so far 
indicated regulation of Stmn1 transcription by Kpna2-mediated nuclear import. Reflecting the human 
in vivo situation, Kpna2 expression was only enhanced in a subset of murine HCC samples of this model. 
Complementary, using an E2f1-driven HCC mouse model designed by Conner et al. [77], E2f1-
dependent expression of Stathmin could be confirmed in vivo (Figure 5.16). The observed high 
Stathmin abundance especially in full-blown tumors indicates a steady rise in Stathmin expression in 
the course of HCC progression.  
6.7.2 KPNA2 and stathmin expression are correlated and associated with poor survival in human 
HCCs 
To ultimately correlate the here presented in vitro findings to patient data, tissue microarrays were 
immunoassayed for KPNA2 and stathmin expression, confirming a strong expression of KPNA2 and 
stathmin (Figure 5.17). Interestingly, when samples were grouped according to tumor 
dedifferentiation, a strong positive correlation between abundance of both proteins and tumor grade 
was found. These findings are in line with the in the E2f1-driven HCC mouse model observed stronger 
expression of Stathmin in full blown tumors compared to dysplastic nodules. Taken together, analysis 
of murine and human HCC tissues indicates a steady increase in KPNA2 and stathmin expression during 
cancer progression.  
To confirm the observed data in a larger setup, two independent patient cohorts (Roessler and TCGA 
LIHC cohorts) that together comprise the transcriptomic data of more than 600 individuals were 
analyzed. Patient data of both cohorts revealed strong expression of KPNA2 and STMN1 in HCC 
compared to adjacent non-tumorous tissue and a significant positive correlation of the expression of 
the two proteins (Figure 5.18). Furthermore, high abundance of KPNA2 and STMN1 was associated with 
poor patient outcome. Reflecting the controversially discussed role of E2F1 in HCC, analysis of E2F1 
expression showed no differential expression in the Roessler cohort (data not shown), but a 
significantly higher expression correlated with poor survival in tumor samples of the TCGA LIHC cohort 
(Figure 5.19). As previously mentioned, the vast majority of patients within the Roessler cohort 
developed HCC on the background of HBV infection. Interestingly, Choi et al. demonstrated that direct 
binding of E2F1 to HBx inhibits the HBx-mediated repression of p53 transcription, indicating a 
protective effect of high E2F1 expression in HBV driven hepatocarcinogenesis [150].  For TFDP1, both 
cohorts showed no alterations in RNA levels. However, within the tumor group of the TCGA LIHC cohort, 
high TFDP1 expression was linked to low patient survival, underlining the molecular heterogeneity of 
tumors between individual patients. Overall, the congruent findings in the Roessler and TCGA LIHC 
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cohort substantiate the biological significance of KPNA2 and stathmin especially since the cohorts 
include patients with different tumor etiologies and ethnicities. In conclusion, the strong expression 
and correlation of KPNA2 and stathmin highlights the relevance of the KPNA2-E2F1/TFDP1-stathin axis 
at least in a significant fraction of human HCCs.     
6.8 The KPNA2-E2F1/TFDP1-stathmin axis as potential therapeutic target 
The overexpression of nuclear transport factors as shown here for KPNA2 along with the associated 
protumorigenic properties, the poor overall survival and the reported significance as prognostic 
markers make them valid candidates for targeted cancer therapies [116]. So far, the only available 
compounds are inhibitors of XPO1, karyopherin-beta 2 (KPNB2), karyopherin-beta 1 (KPNB1) and the 
KPNA/KPNB1 complex [51, 51, 116]. Although drugs exist that disrupt the KPNA/KPNB1 transport cycle 
(e.g. cSN50.1, Importazole), development never advanced to the stage of clinical trials [116]. A large 
proportion of research is done on so-called SINE (selective inhibitors of nuclear export) compounds 
targeting XPO1, with the most prominent of them being Selinexor (KPT-330) which is currently tested 
in clinical studies [151]. Zheng et al. studied the effect of Selinexor in HCC cell lines and reported 
reduction of viability and proliferation and PUMA-mediated induction of apoptosis following Selinexor 
treatment [152]. Using in vivo studies in mice, Selinexor was also proven to show potent anti-tumor 
effects after oral administration in pancreatic cancer by mediation of accumulation of the pro-apoptotic 
protein PAR-4 in the nucleus [153]. Similar results were for example found for Selinexor and other SINE 
compounds in triple-negative breast cancer via nuclear sequestration and inhibition of STAT3-mediated 
transcription of surviving and in NSCLC by induction of cell cycle arrest and pro-apoptotic factors [154, 
155]. Currently, clinical trials (phase I and II) are ongoing for treatment of different hematologic and 
solid cancers [151]. As all KPNAs are translocated from the nucleus to the cytoplasm by XPO2 (KPNA-
XPO2-RanGTP complex), which was previously shown to be highly expressed and of functional 
relevance in HCC [53, 61, 156], also inhibition of the KPNA-XPO2 interaction could be a promising 
therapeutic strategy. Using a chemo-proteomic approach, Tian et al. recently identified gambogic acid 
as potent inhibitor of XPO2 and demonstrated that gambogic acid treatment interrupts the 
XPO2/KPNA2 transport cycle by accumulation of both proteins in the nucleus [157]. However, due to 
the broad range of biological effects of gambogic acid (e.g. inhibition of topoisomerase IIa and Bcl-2, 
modulation of NFκB signaling) [157, 158], isolated investigation of the effects of KPNA2 inhibition on 
tumor treatment is challenging and needs further investigation.   
The role of E2F1 in HCC is controversially discussed. As shown based on the TCGA LIHC data, E2F1 is 
overexpressed in HCC compared to adjacent non-tumorous tissue and high expression of E2F1 is related 
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to poor patient outcome. Moreover, E2F1 was shown to transcriptionally activate expression of genes 
involved in enhanced proliferation (e.g. CDC2) and it was previously demonstrated that depletion of 
E2F1 reduces liver cancer cell growth and survival [159]. Controversially, overexpression of E2F1 was 
also linked to pro-apoptotic features in HCC [159]. In the above-mentioned mouse model of 
Conner et al., authors showed that E2F1 signaling exerts proliferative and pro-apoptotic effects of E2F1 
overexpression in different stages of hepatocarcinogenesis [77]. Conducting an in vitro study on 
Sorafenib in HCC Zhai et al. found that Sorafenib exerts its anti-cancer properties by inhibition of E2F1 
[160]. However, due to the dual role of E2F1 in HCC downstream effectors/target genes of E2F1 could 
represent more eligible targets for future therapies. Thus, one option would be to target stathmin 
directly. Different studies showed that silencing of stathmin results, next to the here demonstrated 
inhibition of clonogenicity, in cell cycle arrest and apoptosis [71]. Based on their role in mitosis, 
microtubules are established targets in cancer therapy by treatment with destabilizing (vinca alkaloids, 
e.g. Vinblastin) or stabilizing (taxanes, e.g. Paclitaxel) compounds which ultimately induce apoptosis in 
dividing cells [161]. Like for many chemotherapeutic agents, also resistance of cancer cells to 
microtubule inhibitors have been reported [71]. Several studies demonstrated that overexpression of 
stathmin in solid tumors reduces sensitivity of cancer cells to treatment with taxanes while divergent 
reports exist for the interaction of stathmin and vinca alkaloids [162, 163]. In line with the reported 
inhibition of taxane activity by stathmin, Wang et al. demonstrated that stathmin depletion sensitizes 
osteosarcoma cells for taxane treatment [164]. Thus, development of a potent stathmin inhibitor could 
represent a viable candidate for combinational therapy.  
Since KPNA2 exerts its function upstream of E2F1, stathmin and other oncogenic factors, targeting 
KPNA2 could have a substantial effect on tumor cells. So far, Sorafenib, and Regorafenib as second-line 
treatment, are the only available drugs for systemic treatment of advanced HCC, both extending overall 
survival only for roughly three months [41, 42]. Therefore, there is an urgent need for development of 
novel and more selective compounds for (targeted) therapy of HCC. Though extensively more research 
is needed, targeting KPNA2 and other karyopherins, which play a critical role in tumorigenesis by 
translocation of oncogenes and tumor suppressors [75], could provide a future perspective for selective 
treatment of liver cancer.  
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Table A.1: List of most downregulated proteins following KPNA2 depletion as analyzed by quantitative 
proteomics. adj. p-value: adjusted p-value. 
ID fold change [log2] p-value adj. p-value short name 
P52292 -4.06652799 2.22E-08 3.91E-05 IMA1_HUMAN 
Q13247 -2.086579987 0.01177021 0.21331985 SRSF6_HUMAN 
Q8WW33 -1.469968789 0.00435593 0.16302233 GTSF1_HUMAN 
O00560 -1.390320354 0.00016865 0.0707303 SDCB1_HUMAN 
P20700 -1.31021712 5.52E-05 0.04182953 LMNB1_HUMAN 
P28074 -1.166164952 0.00298521 0.15727965 PSB5_HUMAN 
P62314 -1.094443804 0.05202138 0.36435692 SMD1_HUMAN 
Q9Y4E8 -1.062159153 0.03505649 0.33313144 UBP15_HUMAN 
Q9Y4Z0 -1.008477528 0.00051366 0.08032323 LSM4_HUMAN 
Q10471 -1.007840338 0.00046061 0.08032323 GALT2_HUMAN 
P30154 -0.957951503 0.00061188 0.08274524 2AAB_HUMAN 
P16949 -0.924246545 0.00347536 0.15727965 STMN1_HUMAN 
P29590 -0.918142433 0.04884305 0.36117836 PML_HUMAN 
P20618 -0.863252271 0.08238103 0.42518835 PSB1_HUMAN 
Q99436 -0.809284713 0.09842096 0.44565474 PSB7_HUMAN 
P62847 -0.795179066 0.13272856 0.50303967 RS24_HUMAN 
Q9UMY4 -0.79109985 0.01681844 0.26165324 SNX12_HUMAN 
Q9Y508 -0.785957085 0.0054811 0.18051136 RN114_HUMAN 
Q15269 -0.783813019 0.0207403 0.28120308 PWP2_HUMAN 
Q13509 -0.767898445 0.03317723 0.32693324 TBB3_HUMAN 
Q53GQ0 -0.761867846 0.04233141 0.34514615 DHB12_HUMAN 
P49589 -0.757038963 0.04747328 0.35973287 SYCC_HUMAN 
O94905 -0.751309351 0.00585276 0.18051136 ERLN2_HUMAN 
P46783 -0.745375832 0.02355126 0.29019833 RS10_HUMAN 
Q13620 -0.741820141 0.01586513 0.25355364 CUL4B_HUMAN 
Q96PD2 -0.738805068 0.05990561 0.38735155 DCBD2_HUMAN 
P17858 -0.726751287 0.0085131 0.19754389 PFKAL_HUMAN 
P14174 -0.721575039 0.08319954 0.42518835 MIF_HUMAN 
Q9UHD1 -0.712569683 0.00149226 0.12492383 CHRD1_HUMAN 
Q9Y617 -0.695984681 0.00020117 0.0707303 SERC_HUMAN 
P48449 -0.692810446 0.02387647 0.29149185 ERG7_HUMAN 
Q13404 -0.688605589 0.00045027 0.08032323 UB2V1_HUMAN 
P16401 -0.687965271 0.05514733 0.37531168 H15_HUMAN 
Q9BVP2 -0.681372826 0.03195762 0.32121512 GNL3_HUMAN 
P22392 -0.67443197 0.00707494 0.1863338 NDKB_HUMAN 
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Table A.2: List of most upregulated proteins following KPNA2 depletion as analyzed by quantitative 
proteomics. adj. p-value: adjusted p-value. 
ID fold change [log2] p-value adj. p-value short name 
P04908 1.167055939 0.0250581 0.29518733 H2A1B_HUMAN 
Q9NQW6 1.079326388 0.0395878 0.34283422 ANLN_HUMAN 
Q99661 1.028898034 0.01092308 0.20890123 KIF2C_HUMAN 
Q9UKA9 0.999421233 0.0045918 0.16817467 PTBP2_HUMAN 
P61513 0.983972061 0.0616739 0.39426441 RL37A_HUMAN 
Q9BS26 0.971714852 0.00435839 0.16302233 ERP44_HUMAN 
P29992 0.91177934 0.07054658 0.40869439 GNA11_HUMAN 
O14907 0.84958316 0.00370485 0.16085146 TX1B3_HUMAN 
P53814 0.840950498 0.00527634 0.18036487 SMTN_HUMAN 
P24928 0.808662706 0.01004873 0.20305363 RPB1_HUMAN 
P21980 0.806458348 0.00051554 0.08032323 TGM2_HUMAN 
Q9ULW0 0.803453446 7.14E-05 0.04182953 TPX2_HUMAN 
O75607 0.783219728 0.00769629 0.19328676 NPM3_HUMAN 
O94760 0.782676485 0.00690763 0.1863338 DDAH1_HUMAN 
Q15437 0.767441695 0.00101332 0.10478948 SC23B_HUMAN 
Q969G3 0.766420203 0.05385049 0.37125163 SMCE1_HUMAN 
Q9P035 0.759124722 0.00143272 0.12492383 HACD3_HUMAN 
Q9NUQ9 0.755571782 0.00692104 0.1863338 FA49B_HUMAN 
Q9Y5J7 0.752409982 0.00232429 0.15715779 TIM9_HUMAN 
Q9UI42 0.741567824 0.00854001 0.19754389 CBPA4_HUMAN 
Q9BRP1 0.741163495 0.00284629 0.15727965 PDD2L_HUMAN 
Q96QD8 0.721004462 0.00872268 0.19914888 S38A2_HUMAN 
Q96I24 0.702284924 0.0014667 0.12492383 FUBP3_HUMAN 
Q9H501 0.698070824 0.00037662 0.08032323 ESF1_HUMAN 
P11388 0.682751058 0.00054828 0.08032323 TOP2A_HUMAN 
P14635 0.673542773 0.0150071 0.25000899 CCNB1_HUMAN 
O14617 0.668025863 0.10235619 0.45002029 AP3D1_HUMAN 
Q9Y312 0.663846976 0.17775453 0.5590205 AAR2_HUMAN 
P03956 0.65947673 0.0032367 0.15727965 MMP1_HUMAN 
Q92804 0.65794589 0.16252235 0.52812254 RBP56_HUMAN 
Q6RFH5 0.656458338 0.15869672 0.52279992 WDR74_HUMAN 
Q92879 0.642268976 0.13078413 0.50303967 CELF1_HUMAN 
P61204 0.606797204 0.01086535 0.20890123 ARF3_HUMAN 
P00367 0.588374932 0.05252546 0.36497926 DHE3_HUMAN 
O94973 0.578610725 0.08951013 0.44314581 AP2A2_HUMAN 
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Figure A.1: Publicly available ChIP-Seq datasets reveal binding sites for E2F1 within the STMN1 promoter 
region. Green line: STMN1 gene including regulator regions. STMN1 [+12]: start codon plus 12 kbp. GEO: 
gene omnibus accession number. 
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